⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12943440 | 1.00 | — | — | |
| SCHEMBL15691537 | 1.00 | — | — | |
| SCHEMBL12837178 | 1.00 | — | — | |
| SCHEMBL9605756 | 1.00 | — | — | |
| Water SCHEMBL9832507 | 0.96 | — | — | |
| SCHEMBL975833 | 0.95 | — | — | |
| SCHEMBL2175588 | 0.86 | — | — | |
| SCHEMBL16689090 | 0.86 | — | — | |
| SCHEMBL6668924 | 0.84 | — | — | |
| SCHEMBL16878503 | 0.83 | CHRM2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1184 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350357-A | Phenyl ether compound containing hexahydrofuro [3,2-b ] furan structure and application thereof | 沈阳药科大学 | 2025-01-24 | — | — | CN | claimed |
| WO-2024036176-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES, INC. (US) | 2024-02-15 | — | — | WO | claimed |
| EP-4248975-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-111675720-B | Trifluoro sulfonamide hexahydrofuro [3,2-b ] furan photoresist resin monomer and preparation method thereof | 徐州博康信息化学品有限公司 | 2023-01-17 | — | — | CN | claimed |
| US-11542288-B2 | Antiviral compounds | UNIVERSITY OF MASSACHUSETTS (US) | 2023-01-03 | — | — | US | claimed |
| US-20210371439-A1 | Antiviral Compounds | UNIVERSITY OF MASSACHUSETTS | 2021-12-02 | — | — | US | claimed |
| WO-2013096093-A1 | COMPOUNDS AS DGAT-1 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-27 | — | — | WO | claimed |
| EP-2542528-B1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2013-06-19 | — | — | EP | claimed |
| WO-2012152438-A1 | PROCESS FOR THE PREPARATION OF NITRATE ACID ESTER OF ORGANIC COMPOUNDS | NICOX S.A. (FR) | 2012-11-15 | — | — | WO | claimed |
| EP-1889845-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SmithKline Beecham P.L.C. (GB) | 2008-02-20 | — | — | EP | claimed |
| EP-1538150-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2007-06-27 | — | — | EP | claimed |
| US-7033726-B2 | Photoresist polymeric compound and photoresist resin composition | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-04-25 | — | — | US | claimed |
| EP-1584634-A1 | POLYMERIC COMPOUND FOR PHOTORESIST AND RESIN COMPOSITION FOR PHOTORESIST | Daicel Chemical Industries, Ltd. (JP) | 2005-10-12 | — | — | EP | claimed |
| EP-1538150-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-08 | — | — | EP | claimed |
| US-6900345-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-05-31 | — | — | US | claimed |
| US-20050014087-A1 | Photoresist polymeric compound and photoresist resin composition | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2005-01-20 | — | — | US | claimed |
| US-20040024059-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | claimed |
| EP-1351959-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-10-15 | — | — | EP | claimed |
| WO-2002030929-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | claimed |
| JP-8231550-A | — | — | None | — | — | JP | disclosed |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2026081714-A1 | PHENYL ETHER COMPOUND CONTAINING HEXAHYDROFURO[3,2-B]FURAN STRUCTURE AND USE THEREOF | 沈阳药科大学 | 2026-04-23 | — | — | WO | disclosed |
| WO-2026081714-A1 | PHENYL ETHER COMPOUND CONTAINING HEXAHYDROFURO[3,2-B]FURAN STRUCTURE AND USE THEREOF | 沈阳药科大学 | 2026-04-23 | — | — | WO | disclosed |
| EP-4722269-A1 | RESIN COMPOSITION | Daicel Corporation (JP) | 2026-04-08 | — | — | EP | disclosed |
| US-12577219-B2 | Macrolide brefeldin a ester derivatives and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2026-03-17 | — | — | US | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4025575-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-119350357-B | Phenyl ether compound containing hexahydrofuro [3,2-b ] furan structure and application thereof | 沈阳药科大学 | 2025-10-31 | — | — | CN | disclosed |
| CN-119350357-B | Phenyl ether compound containing hexahydrofuro [3,2-b ] furan structure and application thereof | 沈阳药科大学 | 2025-10-31 | — | — | CN | disclosed |
| EP-2958562-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-114728918-B | RIP1 inhibitory compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-112368278-B | RIP1 inhibitory compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-12297202-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4025574-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-114728958-B | RIP1 inhibitory compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4267574-B1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2025047574-A1 | CURABLE EPOXY COMPOSITION | 株式会社ダイセル | 2025-03-06 | — | — | WO | disclosed |
| US-20250075034-A1 | Process for Preparing a Polyurea | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2025-03-06 | — | — | US | disclosed |
| US-20250034100-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-01-30 | — | — | US | disclosed |
| CN-119350357-A | Phenyl ether compound containing hexahydrofuro [3,2-b ] furan structure and application thereof | 沈阳药科大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-119350357-A | Phenyl ether compound containing hexahydrofuro [3,2-b ] furan structure and application thereof | 沈阳药科大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-119350357-A | Phenyl ether compound containing hexahydrofuro [3,2-b ] furan structure and application thereof | 沈阳药科大学 | 2025-01-24 | — | — | CN | disclosed |
| WO-2024247925-A1 | RESIN COMPOSITION | 株式会社ダイセル | 2024-12-05 | — | — | WO | disclosed |
| US-20240383885-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | MAKSCIENTIFIC, LLC | 2024-11-21 | — | — | US | disclosed |
| US-20240368119-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-12116354-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| CN-113620944-B | Novel RET inhibitors, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-3805234-B1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO LTD (CN) | 2024-09-04 | — | — | EP | disclosed |
| CN-113620945-B | RET inhibitor, pharmaceutical composition thereof and application of RET inhibitor in medicines | 广东东阳光药业股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-112574236-B | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-12054480-B2 | Compounds for treating cannabinoid toxicity and acute cannabinoid overdose | MAKSCIENTIFIC, LLC (US) | 2024-08-06 | — | — | US | disclosed |
| US-12043632-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-114292212-B | Compounds containing cyclic structural motifs, urethane/ureido linking units and free radically polymerizable functional groups | 阿科玛法国公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-2964224-B1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2024-07-03 | — | — | EP | disclosed |
| US-20240210824-A1 | CARBOXYLATE, CARBOXYLIC ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240180882-A1 | COMPOUNDS FOR PROTECTION OF NOISE-INDUCED HEARING-LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240132662-A1 | POLYCARBONATE AND METHOD FOR PREPARING SAME | LG CHEM, LTD. (KR) | 2024-04-25 | — | — | US | disclosed |
| CN-117849914-A | Anti-reflective material | 株式会社大赛璐 | 2024-04-09 | — | — | CN | disclosed |
| WO-2024036176-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20240043745-A1 | USE OF EUGENOL DERIVATIVES AS STABILIZERS, ORGANIC MATERIAL AND EUGENOL DERIVATIVES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2024-02-08 | — | — | US | disclosed |
| CN-117510500-A | Preparation method of asperazepanones alkaloid and application of asperazepanones alkaloid as anti-inflammatory drug | 中国海洋大学 | 2024-02-06 | — | — | CN | disclosed |
| WO-2024017706-A1 | METHOD FOR PRODUCING A COMPOSITE COMPONENT WITH A SUPPORT COMPRISING POLYCARBONATE OF A SPECIFIC OH CONTENT | COVESTRO DEUTSCHLAND AG (DE) | 2024-01-25 | — | — | WO | disclosed |
| EP-4309865-A1 | METHOD FOR PRODUCING A COMPOSITE ARTICLE COMPRISING A SUPPORT COMPRISING A HYDROXYL COMPONENT | Covestro Deutschland AG (DE) | 2024-01-24 | — | — | EP | disclosed |
| EP-4309864-A1 | METHOD FOR PRODUCING A COMPOSITE ARTICLE COMPRISING A SUPPORT COMPRISING POLYCARBONATE WITH SPECIFIC OH CONTENT | Covestro Deutschland AG (DE) | 2024-01-24 | — | — | EP | disclosed |
| EP-4286449-A1 | POLYCARBONATE AND METHOD FOR PREPARING SAME | Lg Chem, Ltd. (KR) | 2023-12-06 | — | — | EP | disclosed |
| EP-4267574-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230340177-A1 | COMPOSITION AND SILOXANE-BASED THERMOPLASTIC RESIN USING SAME, AND METHODS FOR PRODUCING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230340177-A1 | COMPOSITION AND SILOXANE-BASED THERMOPLASTIC RESIN USING SAME, AND METHODS FOR PRODUCING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11777142-B2 | Gelable system containing ether compounds, preparation method therefor and use thereof | BEIJING NORMAL UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11777142-B2 | Gelable system containing ether compounds, preparation method therefor and use thereof | BEIJING NORMAL UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| EP-4248975-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11767296-B2 | Heteroaryl compounds as kinase inhibitor | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2023-09-26 | — | — | US | disclosed |
| US-11767296-B2 | Heteroaryl compounds as kinase inhibitor | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2023-09-26 | — | — | US | disclosed |
| CN-116761835-A | Polycarbonate and process for producing the same | 株式会社LG化学 | 2023-09-15 | — | — | CN | disclosed |
| CN-116726010-A | Application of macrolide derivative in preparation of medicines for inhibiting pro-inflammatory cytokine acting agents | 中国海洋大学 | 2023-09-12 | — | — | CN | disclosed |
| EP-4237484-A1 | USE OF EUGENOL DERIVATIVES AS STABILIZERS, ORGANIC MATERIAL AND EUGENOL DERIVATIVES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-09-06 | — | — | EP | disclosed |
| EP-3571205-B1 | THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-20230265100-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3496943-B1 | COMPOUNDS CONTAINING CYCLIC STRUCTURAL ELEMENTS, URETHANE/UREIDO LINKAGES AND A FREE RADICAL-POLYMERIZABLE FUNCTIONAL GROUP | ARKEMA FRANCE (FR) | 2023-08-09 | — | — | EP | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| WO-2023138689-A1 | COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF PROTEIN LPA(APO(A)) | 上海舶望制药有限公司 | 2023-07-27 | — | — | WO | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230212203-A1 | Antiviral Compounds | UNIVERSITY OF MASSACHUSETTS | 2023-07-06 | — | — | US | disclosed |
| US-11679108-B2 | Aromatic heterocyclic compound, and pharmaceutical composition and use thereof | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-06-20 | — | — | US | disclosed |
| US-11680039-B2 | Compounds containing cyclic structural elements, urethane/ureido linkages and a free radical-polymerizable functional group | ARKEMA FRANCE (FR) | 2023-06-20 | — | — | US | disclosed |
| WO-2023102024-A1 | POLY(β-AMINO ESTER) MICROPARTICLES FOR MICRONUTRIENT FORTIFICATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-08 | — | — | WO | disclosed |
| US-11667643-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230167235-A1 | Polyester Carbonates Having a Defined Proportion of Ester Groups | COVESTRO DEUTSCHLAND AG (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230145772-A1 | Polyester Carbonates Consisting of Different Diols in a Defined Ratio | COVESTRO DEUTSCHLAND AG (DE) | 2023-05-11 | — | — | US | disclosed |
| EP-4175714-A1 | RIP1K INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2023-05-10 | — | — | EP | disclosed |
| EP-4172162-A1 | AMPK ACTIVATORS | Kallyope, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| CN-113292422-B | Allylation coupling reaction method and application thereof | 南方科技大学 | 2023-04-28 | — | — | CN | disclosed |
| US-20230112865-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | MIDCAP FINANCIAL TRUST | 2023-04-13 | — | — | US | disclosed |
| US-20230113841-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-111153891-B | Substituted benzimidazole PI3K alpha/mTOR double-target inhibitor and pharmaceutical composition and application thereof | 贵州医科大学 | 2023-03-31 | — | — | CN | disclosed |
| US-20230099203-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| WO-2023020486-A1 | RIP1 KINASE INHIBITOR COMPOUND AND COMPOSITION AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2023-02-23 | — | — | WO | disclosed |
| WO-2023006250-A1 | OXIDATION-STABLE DIANHYDROHEXITOL COMPOSITION CONTAINING GALLIC ACID ESTER | ROQUETTE FRERES (FR) | 2023-02-02 | — | — | WO | disclosed |
| US-11566145-B2 | Polyurethane coating compositions and their use as gel coats | COVESTRO LLC (US) | 2023-01-31 | — | — | US | disclosed |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| CN-111675720-B | Trifluoro sulfonamide hexahydrofuro [3,2-b ] furan photoresist resin monomer and preparation method thereof | 徐州博康信息化学品有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-111675720-B | Trifluoro sulfonamide hexahydrofuro [3,2-b ] furan photoresist resin monomer and preparation method thereof | 徐州博康信息化学品有限公司 | 2023-01-17 | — | — | CN | disclosed |
| EP-3708602-B1 | PROCESS FOR PRODUCING POLYCYCLIC POLYETHER POLYOLS | COVESTRO LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11542288-B2 | Antiviral compounds | UNIVERSITY OF MASSACHUSETTS (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022268088-A1 | TRICYCLIC COMPOUND USED AS GPR84 ANTAGONIST | 武汉人福创新药物研发中心有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-11518873-B2 | Curable compositions | ARKEMA FRANCE (FR) | 2022-12-06 | — | — | US | disclosed |
| CN-115279763-A | RIP1 inhibiting compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-11472782-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| WO-2022192079-A1 | COMPOUNDS FOR PROTECTION OF NOISE-INDUCED HEARING-LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022184000-A1 | IMIDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2022-09-09 | — | — | WO | disclosed |
| US-11407736-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| WO-2022164072-A1 | POLYCARBONATE AND METHOD FOR PREPARING SAME | 주식회사 엘지화학 | 2022-08-04 | — | — | WO | disclosed |
| EP-4026837-A1 | PROCESS FOR PRODUCING 2,5-DIAMINO-2,5-DIDEOXY-1,4:3,6-DIANHYDROHEXITOL | Covestro Deutschland AG (DE) | 2022-07-13 | — | — | EP | disclosed |
| EP-4025568-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4025574-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4025575-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-114728958-A | RIP1 inhibiting compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728918-A | RIP1 inhibiting compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-11377428-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-11370765-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370764-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370740-B2 | Method for producing ester group-containing compound | DIC CORPORATION (JP) | 2022-06-28 | — | — | US | disclosed |
| CN-112142784-B | Asymmetric reduction of nitrogen-phosphono-protected imines | 南方科技大学 | 2022-06-17 | — | — | CN | disclosed |
| US-11352371-B2 | Thienopyrimidine derivatives as ACC inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11353738-B2 | Optical film, polarizing plate, liquid crystal panel, touch panel, and image display device | FUJIFILM CORPORATION (JP) | 2022-06-07 | — | — | US | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11339245-B2 | Monomer mixture and curable composition containing same | DAICEL CORPORATION (JP) | 2022-05-24 | — | — | US | disclosed |
| US-11332451-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (GA) | 2022-05-17 | — | — | US | disclosed |
| WO-2022090566-A1 | USE OF EUGENOL DERIVATIVES AS STABILIZERS, ORGANIC MATERIAL AND EUGENOL DERIVATIVES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-05-05 | — | — | WO | disclosed |
| CN-114292212-A | Compounds containing cyclic structural units, urethane/ureido linking units and free-radically polymerizable functional groups | 阿科玛法国公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20220088008-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2022-03-24 | — | — | US | disclosed |
| US-20220064138-A1 | MACROLIDE BREFELDIN A ESTER DERIVATIVES AND USE THEREOF | OCEAN UNIVERSITY OF CHINA (CN) | 2022-03-03 | — | — | US | disclosed |
| EP-3177614-B1 | FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220033393-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | MAKSCIENTIFIC, LLC | 2022-02-03 | — | — | US | disclosed |
| CN-109562596-B | Compounds containing cyclic structural units, urethane/ureido linking units and free-radically polymerizable functional groups | 阿科玛法国公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11225471-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20220009936-A1 | RIP1K INHIBITORS | MIDCAP FINANCIAL TRUST | 2022-01-13 | — | — | US | disclosed |
| WO-2022005898-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20210403409-A1 | METHOD FOR PRODUCING CARBONATE DERIVATIVE | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2021-12-30 | — | — | US | disclosed |
| WO-2021259309-A1 | GLP-1 RECEPTOR AGONIST, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2021-12-30 | — | — | WO | disclosed |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| WO-2021254894-A1 | POLYESTER CARBONATES CONSISTING OF DIFFERENT DIOLS IN A DEFINED RATIO | COVESTRO DEUTSCHLAND AG (DE) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021254891-A1 | POLYESTER CARBONATES HAVING A DEFINED PROPORTION OF ESTER GROUPS | COVESTRO DEUTSCHLAND AG (DE) | 2021-12-23 | — | — | WO | disclosed |
| US-20210388159-A1 | METHOD FOR PRODUCING POLYCARBONATE | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2021-12-16 | — | — | US | disclosed |
| US-20210371439-A1 | Antiviral Compounds | UNIVERSITY OF MASSACHUSETTS | 2021-12-02 | — | — | US | disclosed |
| US-20210346335-A1 | METHODS OF USING NITRIC OXIDE DONOR COMPOUNDS FOR TREATMENT OF COVID-19 AND OTHER INFECTIOUS DISEASES | COEURATIVE, INC. (US) | 2021-11-11 | — | — | US | disclosed |
| EP-2970119-B1 | NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20210292623-A1 | BIO-BASED COATINGS AND ADHESIVES USING OILS OF PHYSARIA FENDLERI AND EUPHORBIA LAGASCAE | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2021-09-23 | — | — | US | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3700506-B1 | TOPICAL FORMULATIONS FOR TREATING DERMATOLOGICAL DISORDERS INCLUDING MALE PATTERN BALDNESS | XYON HEALTH INC (CA) | 2021-09-08 | — | — | EP | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-11092845-B2 | Liquid crystal panel and image display device | FUJIFILM CORPORATION (JP) | 2021-08-17 | — | — | US | disclosed |
| US-20210238128-A1 | COMPOUNDS CONTAINING CYCLIC STRUCTURAL ELEMENTS, URETHANE/UREIDO LINKAGES AND A FREE RADICAL-POLYMERIZABLE FUNCTIONAL GROUP | ARKEMA FRANCE (FR) | 2021-08-05 | — | — | US | disclosed |
| US-20210238153-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-11040028-B2 | Penicinotam derivative, preparation method and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2021-06-22 | — | — | US | disclosed |
| EP-3835302-A1 | DIISOCYANATE COMPOUND HAVING ANHYDROSUGAR ALCOHOL CORE AND PREPARATION METHOD THEREFOR | Samyang Corporation (KR) | 2021-06-16 | — | — | EP | disclosed |
| US-11028285-B2 | Urethane (meth)acrylate and active energy ray-curable resin composition | DAICELL-ALLNEX LTD. (JP) | 2021-06-08 | — | — | US | disclosed |
| US-20210163820-A1 | LIQUID-CRYSTALLINE MEDIUM FOR USE IN A SWITCHING ELEMENT | MERCK PATENT GMBH (DE) | 2021-06-03 | — | — | US | disclosed |
| WO-2021104529-A1 | MACROLIDE BREFELDIN A ESTER DERIVATIVE, AND USE | 中国海洋大学 | 2021-06-03 | — | — | WO | disclosed |
| US-20210157201-A1 | LIQUID CRYSTAL PANEL AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2021-05-27 | — | — | US | disclosed |
| US-10993938-B2 | Lactam compound, preparation method and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2021-05-04 | — | — | US | disclosed |
| US-20210115337-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| EP-3805234-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Guangzhou Henovcom Bioscience Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-10968206-B2 | Cannabinergic nitrate esters and related analogs | NORTHEASTERN UNIVERSITY (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968232-B2 | Antidiabetic spirochroman compounds | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2021057970-A1 | RET INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 广东东阳光药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-20210094938-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-04-01 | — | — | US | disclosed |
| WO-2021046382-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046437-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046407-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210069208-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210070735-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| EP-3788044-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210053990-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-3313832-B1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3162830-B1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORP (JP) | 2021-02-24 | — | — | EP | disclosed |
| EP-3670566-B1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORP (JP) | 2021-02-24 | — | — | EP | disclosed |
| WO-2021030142-A1 | THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| EP-2906040-B1 | NOVEL BENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | MERCK SHARP & DOHME (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210040053-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-02-11 | — | — | US | disclosed |
| US-10913817-B2 | Use of a composition of low-viscosity bis-anhydrohexitol ethers as a reactive diluent for crosslinkable resin, adhesive, coating and matrix compositions for composites | ROQUETTE FRERES (FR) | 2021-02-09 | — | — | US | disclosed |
| US-20210009537-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210008045-A1 | PANICINOTAM DERIVATIVE, PREPARATION METHOD AND USE THEREOF | OCEAN UNIVERSITY OF CHINA (CN) | 2021-01-14 | — | — | US | disclosed |
| US-20210011337-A1 | OPTICAL FILM, POLARIZING PLATE, LIQUID CRYSTAL PANEL, TOUCH PANEL, AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2021-01-14 | — | — | US | disclosed |
| US-20210002237-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20210002236-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-10882953-B2 | Monomer composition and curable composition containing same | DAICEL CORPORATION (JP) | 2021-01-05 | — | — | US | disclosed |
| US-20200407332-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-10815206-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| EP-2880028-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-3709995-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2020-09-23 | — | — | EP | disclosed |
| WO-2020185995-A1 | POLYURETHANE COATING COMPOSITIONS AND THEIR USE AS GEL COATS | COVESTRO LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20200291260-A1 | POLYURETHANE COATING COMPOSITIONS AND THEIR USE AS GEL COATS | COVESTRO LLC | 2020-09-17 | — | — | US | disclosed |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MERCK SHARP & DOHME CORP. (US) | 2020-09-10 | — | — | US | disclosed |
| US-10759812-B2 | Thienopyrimidine derivative and use thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| EP-3162822-B1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORP (JP) | 2020-08-26 | — | — | EP | disclosed |
| EP-3102198-B1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200230925-A1 | LAMINATED BODY AND FLEXIBLE DEVICE PROVIDED WITH SAID LAMINATED BODY | DAICEL CORPORATION (JP) | 2020-07-23 | — | — | US | disclosed |
| EP-3430076-B1 | COMPOSITION AND METHOD FOR MANUFACTURING SULFONE POLYMER MEMBRANE | SOLVAY SPECIALTY POLYMERS IT (IT) | 2020-07-15 | — | — | EP | disclosed |
| EP-3670566-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | Daicel Corporation (JP) | 2020-06-24 | — | — | EP | disclosed |
| EP-3191483-B1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | NORTH & SOUTH BROTHER PHARMACY INVESTMENT CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| EP-3663325-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | Daicel Corporation (JP) | 2020-06-10 | — | — | EP | disclosed |
| US-10676458-B2 | Antidiabetic bicyclic compounds | Merch Sharp & Dohne Corp. Rahway (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3654968-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | Merck Sharp & Dohme Corp. (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20200123308-A1 | USE OF A COMPOSITION OF LOW-VISCOSITY BIS-ANHYDROHEXITOL ETHERS AS A REACTIVE DILUENT FOR CROSSLINKABLE RESIN, ADHESIVE, COATING AND MATRIX COMPOSITIONS FOR COMPOSITES | ROQUETTE FRERES (FR) | 2020-04-23 | — | — | US | disclosed |
| US-20200099090-A1 | FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND PREPARATION METHOD THEREOF | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | disclosed |
| US-20200099096-A1 | Gelable System Containing Ether Compounds, Preparation Method Therefor and Use Thereof | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | disclosed |
| WO-2020055178-A1 | DIOL COMPOUND, POLYCARBONATE, AND METHOD FOR PRODUCING SAME | 주식회사 엘지화학 | 2020-03-19 | — | — | WO | disclosed |
| EP-2768307-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200071453-A1 | MONOMER MIXTURE AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORPORATION (JP) | 2020-03-05 | — | — | US | disclosed |
| US-10578914-B2 | Liquid crystal panel and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2020-03-03 | — | — | US | disclosed |
| US-20200055977-A1 | MONOMER MIXTURE AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORPORATION (JP) | 2020-02-20 | — | — | US | disclosed |
| WO-2020032611-A1 | DIISOCYANATE COMPOUND HAVING ANHYDROSUGAR ALCOHOL CORE AND PREPARATION METHOD THEREFOR | 주식회사 삼양사 | 2020-02-13 | — | — | WO | disclosed |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200030312-A1 | Lactam Compound, Preparation Method and Use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2020-01-30 | — | — | US | disclosed |
| US-10544158-B1 | Process for producing polycyclic polyether polyols | COVESTRO LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190352311-A1 | THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3248999-B1 | NOVEL METHOD FOR PREPARING HIGHLY TRANSPARENT AND HIGHLY HEAT-RESISTANT POLYCARBONATE ESTER | SK CHEMICALS CO LTD (KR) | 2019-11-20 | — | — | EP | disclosed |
| US-10479908-B2 | Method of manufacturing hard coat film | FUJIFILM CORPORATION (JP) | 2019-11-19 | — | — | US | disclosed |
| US-20190346592-A1 | OPTICAL FILM AND FRONT PANEL OF IMAGE DISPLAY APPARATUS, IMAGE DISPLAY APPARATUS, MIRROR WITH IMAGE DISPLAY FUNCTION, RESISTIVE FILM-TYPE TOUCH PANEL, AND CAPACITANCE-TYPE TOUCH PANEL HAVING OPTICAL FILM | FUJIFILM CORPORATION (JP) | 2019-11-14 | — | — | US | disclosed |
| US-10472466-B2 | Monomer composition and curable composition containing same | DAICEL CORPORATION (JP) | 2019-11-12 | — | — | US | disclosed |
| US-20190337961-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| US-20190337907-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2019-11-07 | — | — | US | disclosed |
| EP-3558298-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190324598-A1 | OPTICAL FILM AND FRONT PANEL OF IMAGE DISPLAY APPARATUS, IMAGE DISPLAY APPARATUS, MIRROR WITH IMAGE DISPLAY FUNCTION, RESISTIVE FILM-TYPE TOUCH PANEL, AND CAPACITANCE-TYPE TOUCH PANEL HAVING OPTICAL FILM | FUJIFILM CORPORATION (JP) | 2019-10-24 | — | — | US | disclosed |
| US-20190315959-A1 | CURABLE COMPOSITIONS | ARKEMA FRANCE (FR) | 2019-10-17 | — | — | US | disclosed |
| EP-3545042-A1 | CURABLE COMPOSITIONS | Arkema France (FR) | 2019-10-02 | — | — | EP | disclosed |
| WO-2019174601-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITOR | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2019-09-19 | — | — | WO | disclosed |
| EP-2887807-B1 | BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES USEFUL AS AMP-ACTIVATED PROTEIN KINASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2888007-B1 | BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES USEFUL AS AMP-ACTIVATED PROTEIN KINASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-09-18 | — | — | EP | disclosed |
| US-10406140-B2 | 5-substituted benzimidazole and 5-substituted azabenzimidazole derivative both having AMPK activation effect | SHIONOGI & CO., LTD. (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190255818-A1 | OPTICAL FILM AND FRONT PANEL OF IMAGE DISPLAY APPARATUS, IMAGE DISPLAY APPARATUS, MIRROR WITH IMAGE DISPLAY FUNCTION, RESISTIVE FILM-TYPE TOUCH PANEL, AND CAPACITANCE-TYPE TOUCH PANEL HAVING OPTICAL FILM | FUJIFILM CORPORATION (JP) | 2019-08-22 | — | — | US | disclosed |
| EP-3068768-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20190225596-A1 | Cannabinergic Nitrate Esters And Related Analogs | NORTHEASTERN UNIVERSITY | 2019-07-25 | — | — | US | disclosed |
| US-20190183866-A1 | 5-SUBSTITUTED BENZIMIDAZOLE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE BOTH HAVING AMPK ACTIVATION EFFECT | SHIONOGI & CO., LTD. (JP) | 2019-06-20 | — | — | US | disclosed |
| EP-3496943-A1 | COMPOUNDS CONTAINING CYCLIC STRUCTURAL ELEMENTS, URETHANE/UREIDO LINKAGES AND A FREE RADICAL-POLYMERIZABLE FUNCTIONAL GROUP | Arkema France (FR) | 2019-06-19 | — | — | EP | disclosed |
| EP-3100723-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10315983-B2 | Fatty amino alcohols and process for preparing same | PIVERT S.A.S. (FR) | 2019-06-11 | — | — | US | disclosed |
| US-10316140-B2 | Polyesters comprising 2,5-furandicarboxylate and saturated diol units having a high glass transition temperature | FURANIX TECHNOLOGIES B.V. (NL) | 2019-06-11 | — | — | US | disclosed |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190135826-A1 | PROCESS FOR MANUFACTURING DIANHYDROHEXITOL CRYSTALS WITH A STEP OF EVAPORATIVE CRYSTALLIZATION OF THE FIRST CRYSTALLIZATION MOTHER LIQUORS | ROQUETTE FRERES (FR) | 2019-05-09 | — | — | US | disclosed |
| US-20190135834-A1 | 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE HAVING ???? ACTIVATION ACTION | SHIONOGI & CO., LTD. (JP) | 2019-05-09 | — | — | US | disclosed |
| EP-2785178-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190119443-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORPORATION (JP) | 2019-04-25 | — | — | US | disclosed |
| EP-2888006-B1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES USEFUL AS AMPK ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20190106540-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORPORATION (JP) | 2019-04-11 | — | — | US | disclosed |
| EP-2888005-B1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20190091970-A1 | LAMINATE AND FRONT PANEL OF IMAGE DISPLAY APPARATUS, IMAGE DISPLAY APPARATUS, MIRROR WITH IMAGE DISPLAY FUNCTION, RESISTIVE FILM-TYPE TOUCH PANEL, AND CAPACITANCE-TYPE TOUCH PANEL HAVING LAMINATE | FUJIFILM CORPORATION (JP) | 2019-03-28 | — | — | US | disclosed |
| WO-2019048652-A1 | PURIFICATION METHODS COMPRISING THE USE OF MEMBRANES OBTAINED FROM BIO-BASED SULFONE POLYMERS | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2019-03-14 | — | — | WO | disclosed |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190071412-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-03-07 | — | — | US | disclosed |
| US-10221164-B2 | Cannabinergic nitrate esters and related analogs | NORTHEASTERN UNIVERSITY (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-3436003-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2019-02-06 | — | — | EP | disclosed |
| WO-2019018186-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-01-24 | — | — | WO | disclosed |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2019012560-A1 | AN ISOHEXIDE-DIOXALATE COMPOUND, ITS POLYMERS AND APPLICATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-01-17 | — | — | WO | disclosed |
| EP-2875001-B1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-01-09 | — | — | EP | disclosed |
| EP-2322523-B1 | Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS INC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-10167296-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | EVOTEC INTERNATIONAL GMBH (DE) | 2019-01-01 | — | — | US | disclosed |
| EP-2720539-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3096754-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-10059667-B2 | Antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| US-10053444-B2 | Cannabinergic nitrate esters and related analogs | UNIVERSITY OF CONNECTICUT (US) | 2018-08-21 | — | — | US | disclosed |
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040298-B2 | Inkjet printing device, ink set, and inkjet printing method | MIMAKI ENGINEERING CO., LTD. (JP) | 2018-08-07 | — | — | US | disclosed |
| US-10040298-B2 | Inkjet printing device, ink set, and inkjet printing method | MIMAKI ENGINEERING CO., LTD. (JP) | 2018-08-07 | — | — | US | disclosed |
| WO-2018133858-A1 | THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-07-26 | — | — | WO | disclosed |
| EP-3076959-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2018118670-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| US-10000454-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME (US) | 2018-06-19 | — | — | US | disclosed |
| US-9994773-B2 | Flame retardant block copolymers from renewable feeds | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180159174-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, SECONDARY BATTERY, BATTERY PACK, ELECTRIC VEHICLE, ELECTRIC POWER STORAGE SYSTEM, ELECTRIC POWER TOOL, AND ELECTRONIC APPARATUS | TOHOKU MURATA MANUFACTURING CO., LTD. (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180159174-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, SECONDARY BATTERY, BATTERY PACK, ELECTRIC VEHICLE, ELECTRIC POWER STORAGE SYSTEM, ELECTRIC POWER TOOL, AND ELECTRONIC APPARATUS | TOHOKU MURATA MANUFACTURING CO., LTD. (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180157111-A1 | LIQUID CRYSTAL PANEL AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180157111-A1 | LIQUID CRYSTAL PANEL AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2018-06-07 | — | — | US | disclosed |
| EP-3329918-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2018095823-A1 | CURABLE COMPOSITIONS | ARKEMA FRANCE (FR) | 2018-05-31 | — | — | WO | disclosed |
| EP-2935400-B1 | CROSS-LINKED POLYCARBONATE RESIN WITH IMPROVED CHEMICAL AND FLAME RESISTANCE | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2018-05-30 | — | — | EP | disclosed |
| US-9980948-B2 | Azaindole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9985312-B1 | Non-aqueous electrolytic solution, secondary battery, battery pack, electric vehicle, electric power storage system, electric power tool, and electronic apparatus | MURATA MANUFACTURING CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9985312-B1 | Non-aqueous electrolytic solution, secondary battery, battery pack, electric vehicle, electric power storage system, electric power tool, and electronic apparatus | MURATA MANUFACTURING CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20180142052-A1 | Renewable Bio-Based (Meth)Acrylated Monomers as Vinyl Ester Cross-Linkers | DREXEL UNIVERSITY (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141906-A1 | INDOLE AND AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO. , LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
| EP-3313832-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-3143068-B1 | THERMOPLASTIC AROMATIC POLYESTERS COMPRISING TETRAHYDROFURAN-DIMETHANOL AND FURANDICARBOXYLIC ACID MOTIFS | ROQUETTE FRERES (FR) | 2018-05-02 | — | — | EP | disclosed |
| EP-3313828-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-2875027-B1 | PROCESS FOR HOMOGENEOUSLY CATALYSED AMINATION OF ALCOHOLS WITH AMMONIA IN THE PRESENCE OF A COMPLEX CATALYST WITHOUT ANIONIC LIGANDS | BASF SE (DE) | 2018-05-02 | — | — | EP | disclosed |
| US-9957219-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2742083-B1 | POLYARYLENE ETHER KETONES | SOLVAY SPECIALTY POLYMERS USA (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9951010-B2 | Compounds as CRTH2 antagonist and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20180072028-A1 | HARDCOAT FILM, FRONT PLATE OF IMAGE DISPLAY ELEMENT, RESISTIVE FILM-TYPE TOUCH PANEL, CAPACITANCE-TYPE TOUCH PANEL, AND IMAGE DISPLAY | FUJIFILM CORPORATION (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180072028-A1 | HARDCOAT FILM, FRONT PLATE OF IMAGE DISPLAY ELEMENT, RESISTIVE FILM-TYPE TOUCH PANEL, CAPACITANCE-TYPE TOUCH PANEL, AND IMAGE DISPLAY | FUJIFILM CORPORATION (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-3287462-A1 | ISOSORBIDE DERIVATIVES TO TREAT BACTERIAL BIOFILMS | NITTO DENKO CORPORATION (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-9902712-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| EP-3083584-B1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF TISSUE FIBROSIS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2018-02-21 | — | — | EP | disclosed |
| US-20180044547-A1 | METHOD OF MANUFACTURING HARD COAT FILM | FUJIFILM CORPORATION (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20180044547-A1 | METHOD OF MANUFACTURING HARD COAT FILM | FUJIFILM CORPORATION (JP) | 2018-02-15 | — | — | US | disclosed |
| WO-2018028903-A1 | COMPOUNDS CONTAINING CYCLIC STRUCTURAL ELEMENTS, URETHANE/UREIDO LINKAGES AND A FREE RADICAL-POLYMERIZABLE FUNCTIONAL GROUP | ARKEMA FRANCE (FR) | 2018-02-15 | — | — | WO | disclosed |
| US-9887431-B2 | Non-aqueous electrolytic solution, secondary battery, battery pack, electric vehicle, electric power storage system, electric power tool, and electronic apparatus | MURATA MANUFACTURING CO., LTD. (JP) | 2018-02-06 | — | — | US | disclosed |
| US-9868733-B2 | Azabenzimidazole tetrahydrofuran derivatives | MERCK SHARP & DOHME CORP. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2880030-B1 | BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2018-01-10 | — | — | EP | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9840512-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839642-B2 | Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| EP-3248999-A1 | NOVEL METHOD FOR PREPARING HIGHLY TRANSPARENT AND HIGHLY HEAT-RESISTANT POLYCARBONATE ESTER | SK Chemicals Co., Ltd. (KR) | 2017-11-29 | — | — | EP | disclosed |
| US-20170333398-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170333398-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| EP-3243385-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170322358-A1 | POLARIZING PLATE, FRONT PANEL OF DISPLAY DEVICE, DISPLAY APPARATUS, SUBSTRATE OF TOUCH PANEL, RESISTIVE FILM-TYPE TOUCH PANEL, AND CAPACITANCE-TYPE TOUCH PANEL | FUJIFILM CORPORATION (JP) | 2017-11-09 | — | — | US | disclosed |
| US-20170322358-A1 | POLARIZING PLATE, FRONT PANEL OF DISPLAY DEVICE, DISPLAY APPARATUS, SUBSTRATE OF TOUCH PANEL, RESISTIVE FILM-TYPE TOUCH PANEL, AND CAPACITANCE-TYPE TOUCH PANEL | FUJIFILM CORPORATION (JP) | 2017-11-09 | — | — | US | disclosed |
| EP-2677869-B1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2017187058-A1 | PROCESS FOR MANUFACTURING DIANHYDROHEXITOL CRYSTALS WITH A STEP OF EVAPORATIVE CRYSTALLIZATION OF THE FIRST CRYSTALLIZATION MOTHER LIQUORS | ROQUETTE FRERES (FR) | 2017-11-02 | — | — | WO | disclosed |
| US-9802949-B2 | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-20170306230-A1 | LIQUID-CRYSTALLINE MEDIUM AND HIGH-FREQUENCY COMPONENTS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170298165-A1 | Renewable Bio-Based (Meth)Acrylated Monomers as Vinyl Ester Cross-Linkers | DREXEL UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| WO-2017172505-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170273955-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-20170273955-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-20170267634-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| WO-2017157933-A1 | COMPOSITION AND METHOD FOR MANUFACTURING SULFONE POLYMER MEMBRANE | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017158303-A1 | METHOD FOR PRODUCING DIANHYDROHEXITOL WITH A STEP OF DISTILLATION ON A THIN-FILM EVAPORATOR | ROQUETTE FRERES (FR) | 2017-09-21 | — | — | WO | disclosed |
| EP-2409704-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170260195-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2017-09-14 | — | — | US | disclosed |
| EP-3214076-A1 | HETEROCYCLIC DERIVATIVE HAVING AMPK ACTIVATING EFFECT | Shionogi & Co., Ltd. (JP) | 2017-09-06 | — | — | EP | disclosed |
| WO-2017146186-A1 | 5-PHENYLAZAINDOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | 塩野義製薬株式会社 | 2017-08-31 | — | — | WO | disclosed |
| US-20170247366-A1 | SUBSTITUTED 4-ALKOXYPICOLINAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-08-31 | — | — | US | disclosed |
| US-9738832-B2 | Flame retardant block copolymers from renewable feeds | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2928969-B1 | CROSS-LINKABLE COMPOSITIONS BASED ON DIANHYDROHEXITOL COMPOUNDS | ROQUETTE FRERES (FR) | 2017-08-02 | — | — | EP | disclosed |
| US-20170210728-A1 | Cannabinergic Nitrate Esters And Related Analogs | NORTHEASTERN UNIVERSITY | 2017-07-27 | — | — | US | disclosed |
| US-9708336-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-3187498-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING EFFECT | Shionogi & Co., Ltd. (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | US | disclosed |
| WO-2017105985-A1 | PREPARATION OF ISOHEXIDE-3,6-DICARBALDEHYDES AND ISOHEXIDE-3,6-DIMETHANAMINES | ARCHER DANIELS MIDLAND COMPANY (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170166523-A9 | MEK Inhibitors And Methods Of Their Use | EXELIXIS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170158814-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORPORATION (JP) | 2017-06-08 | — | — | US | disclosed |
| US-20170158814-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORPORATION (JP) | 2017-06-08 | — | — | US | disclosed |
| US-20170158812-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORPORATION (JP) | 2017-06-08 | — | — | US | disclosed |
| US-20170158812-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORPORATION (JP) | 2017-06-08 | — | — | US | disclosed |
| US-20170158812-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORPORATION (JP) | 2017-06-08 | — | — | US | disclosed |
| EP-2865666-B1 | HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-31 | — | — | EP | disclosed |
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-2900656-B1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| US-9650375-B2 | Indole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20170130079-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORPORATION (JP) | 2017-05-11 | — | — | US | disclosed |
| US-20170130079-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORPORATION (JP) | 2017-05-11 | — | — | US | disclosed |
| US-20170130079-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | DAICEL CORPORATION (JP) | 2017-05-11 | — | — | US | disclosed |
| US-20170129994-A1 | POLYESTERS COMPRISING 2,5-FURANDICARBOXYLATE AND SATURATED DIOL UNITS HAVING A HIGH GLASS TRANSITION TEMPERATURE | FURANIX TECHNOLOGIES B.V. (NL) | 2017-05-11 | — | — | US | disclosed |
| EP-3162830-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | Daicel Corporation (JP) | 2017-05-03 | — | — | EP | disclosed |
| EP-3162822-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | Daicel Corporation (JP) | 2017-05-03 | — | — | EP | disclosed |
| EP-3162854-A1 | MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME | Daicel Corporation (JP) | 2017-05-03 | — | — | EP | disclosed |
| EP-2817314-B1 | METHOD OF MAKING ISOIDIDE | STICHTING WAGENINGEN RES (NL) | 2017-04-19 | — | — | EP | disclosed |
| EP-2532657-B9 | Compounds and methods of use | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-04-19 | — | — | EP | disclosed |
| US-20170088736-A1 | INKJET PRINTING DEVICE, INK SET, AND INKJET PRINTING METHOD | MIMAKI ENGINEERING CO., LTD. (JP) | 2017-03-30 | — | — | US | disclosed |
| US-20170088736-A1 | INKJET PRINTING DEVICE, INK SET, AND INKJET PRINTING METHOD | MIMAKI ENGINEERING CO., LTD. (JP) | 2017-03-30 | — | — | US | disclosed |
| WO-2017048675-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-03-23 | — | — | US | disclosed |
| EP-3139918-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2017040459-A1 | IMPROVED SOLUBILITY FOR TARGET COMPOUNDS | Aunova Medchem LLC (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-2945950-B1 | ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI SA (FR) | 2017-03-01 | — | — | EP | disclosed |
| EP-2885305-B1 | METHOD FOR PREPARING DIALKYLOXYDIANHYROHEXITOL BY ETHERIFICATION OF DIANHYDROHEXITOL USING A LIGHT ALCOHOL, IN THE PRESENCE OF AN ACIDIC CATALYST | ROQUETTE FRERES (FR) | 2017-03-01 | — | — | EP | disclosed |
| US-9580400-B2 | Cannabinergic nitrate esters and related analogs | NORTHEASTERN UNIVERSITY (US) | 2017-02-28 | — | — | US | disclosed |
| US-9567300-B2 | Hexahydropentaleno derivatives, preparation method and use in medicine thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-02-14 | — | — | US | disclosed |
| US-20170037024-A1 | Opsin-Binding Ligands, Compositions and Methods for Use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9562022-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9556191-B2 | Aminoquinazoline derivatives and their salts and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| US-9556193-B2 | Benzimidazole hexahydrofuro[3,2-b]furan derivatives | Merck Shapr & Dohme Corp. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9540364-B2 | Benzimidazole tetrahydrofuran derivatives | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540391-B2 | Isomannide derivatives as inhibitors of soluble epoxide hydrolase | SANOFI (FR) | 2017-01-10 | — | — | US | disclosed |
| US-20170001980-A9 | Novel Cannabinergic Nitrate Esters and Related Analogs | UNIVERSITY OF CONNECTICUT | 2017-01-05 | — | — | US | disclosed |
| WO-2016210215-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016210234-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| US-9527839-B2 | Benzimidazole tetrahydropyran derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527875-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2590654-B1 | COMBINATIONS OF KINASE INHIBITORS FOR THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-3102198-A1 | ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160355501-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-12-08 | — | — | US | disclosed |
| EP-3100723-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-3096754-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9499464-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-11-17 | — | — | US | disclosed |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326185-A1 | SYNTHESIS OF ISOHEXIDE DICARBAMATES AND DERIVATIVES THEREOF | ARCHER DANIELS MIDLAND COMPANY | 2016-11-10 | — | — | US | disclosed |
| EP-3082786-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-3076959-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9457004-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160280626-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-09-29 | — | — | US | disclosed |
| EP-3068768-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-09-21 | — | — | EP | disclosed |
| US-9440256-B2 | Method for producing laminate including metallic ink layer | MIMAKI ENGINEERING CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9440256-B2 | Method for producing laminate including metallic ink layer | MIMAKI ENGINEERING CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20160257652-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2016-09-08 | — | — | US | disclosed |
| US-9434695-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-09-06 | — | — | US | disclosed |
| EP-2532657-B1 | Compounds and methods of use | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-08-31 | — | — | EP | disclosed |
| US-9422304-B2 | Synthesis of isohexide dicarbamates and derivatives thereof | ARCHER DANIELS MIDLAND COMPANY (US) | 2016-08-23 | — | — | US | disclosed |
| US-9416139-B2 | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-16 | — | — | US | disclosed |
| EP-2442644-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-9382243-B2 | Azabenzimidazole tetrahydropyran derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-2408300-B1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-05-11 | — | — | EP | disclosed |
| EP-3008072-A1 | SYNTHESIS OF ISOHEXIDE DICARBAMATES AND DERIVATIVES THEREOF | Archer-Daniels-Midland Company (US) | 2016-04-20 | — | — | EP | disclosed |
| US-9309231-B2 | Bridged ring compounds as hepatitis C virus (HCV) inhibitors and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-20160096822-A1 | Novel Cannabinergic Nitrate Esters and Related Analogs | MAKRIYANNIS ALEXANDROS (US) | 2016-04-07 | — | — | US | disclosed |
| US-9303061-B2 | Spiro compounds as Hepatitis C virus inhibitors | Sunshine Luke Pharma Co., Ltd. (CN) | 2016-04-05 | — | — | US | disclosed |
| US-20160083396-A1 | SYNTHESIS OF ISOHEXIDE DICARBAMATES AND DERIVATIVES THEREOF | ARCHER DANIELS MIDLAND CO (US) | 2016-03-24 | — | — | US | disclosed |
| US-9290517-B2 | Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160068708-A1 | URETHANE (METH)ACRYLATE AND ACTIVE ENERGY RAY-CURABLE RESIN COMPOSITION | DAICEL-ALLNEX LTD. (JP) | 2016-03-10 | — | — | US | disclosed |
| WO-2016031842-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING EFFECT | 塩野義製薬株式会社 | 2016-03-03 | — | — | WO | disclosed |
| EP-2990428-A1 | URETHANE (METH)ACRYLATE AND ACTIVE ENERGY RAY-CURABLE RESIN COMPOSITION | Daicel-Allnex Ltd. (JP) | 2016-03-02 | — | — | EP | disclosed |
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-02-11 | — | — | US | disclosed |
| EP-2970119-A1 | NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105263938-A | Synthesis of isohexide dicarbamates and derivatives thereof | ARCHER DANIELS MIDLAND CO | 2016-01-20 | — | — | CN | disclosed |
| US-20160002195-A1 | CANNABINERGIC NITRATE ESTERS AND RELATED ANALOGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-07 | — | — | US | disclosed |
| US-20160002255-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160002224-A1 | NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2016-01-07 | — | — | US | disclosed |
| EP-2963013-A1 | INDOLE AND AZAINDOLE DERIVATIVES EACH HAVING AMPK-ACTIVATING ACTIVITY | Shionogi & Co., Ltd. (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| EP-2958562-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2015200682-A1 | SUBSTITUTED 4-ALKOXYPICOLINAMIDE ANALOGS DS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS | VANDERBILT UNIVERSITY (US) | 2015-12-30 | — | — | WO | disclosed |
| US-20150366834-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| WO-2015176267-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20150336979-A1 | ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI (FR) | 2015-11-26 | — | — | US | disclosed |
| EP-2945950-A1 | ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI (FR) | 2015-11-25 | — | — | EP | disclosed |
| WO-2015171474-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150307509-A1 | FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-29 | — | — | US | disclosed |
| US-20150299215-A1 | SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299118-A1 | HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| US-20150284411-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-10-08 | — | — | US | disclosed |
| US-20150275028-A1 | METHOD OF MANUFACTURING HARD COAT FILM | FUJIFILM CORPORATION (JP) | 2015-10-01 | — | — | US | disclosed |
| US-20150275028-A1 | METHOD OF MANUFACTURING HARD COAT FILM | FUJIFILM CORPORATION (JP) | 2015-10-01 | — | — | US | disclosed |
| EP-2730572-B1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2015-09-16 | — | — | EP | disclosed |
| US-9133082-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2910589-A1 | RESIN COMPOSITION, STRETCHED FILM , CIRCULARLY POLARIZING PLATE, AND IMAGE DISPLAY DEVICE | Mitsubishi Chemical Corporation (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-20150232509-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| EP-2906040-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2015119899-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-08-13 | — | — | WO | disclosed |
| US-20150218149-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | disclosed |
| US-20150218183-A1 | NOVEL BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | disclosed |
| WO-2015112441-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20150210685-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-07-30 | — | — | US | disclosed |
| US-20150203487-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-07-23 | — | — | US | disclosed |
| US-20150203450-A1 | INDOLE AND AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-9085528-B2 | Nitric oxide amino acid ester compound, composition for increasing nitric oxide levels and method of use | ORAL DELIVERY TECHNOLOGY LTD. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085508-B2 | Nitric oxide releasing amino acid ester compound, composition and method of use | ORAL DELIVERY TECHNOLOGY LTD. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150197516-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | Merck Sharp & Dohme Corp. a corporation, a subsidiary of Merck & Co., Inc. | 2015-07-16 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| WO-2015103583-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-09 | — | — | WO | disclosed |
| EP-2888005-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2888006-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2888008-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2887807-A1 | NOVEL BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2888007-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2015089809-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095256-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015084692-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-11 | — | — | WO | disclosed |
| EP-2880028-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2875001-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | Sunshine Lake Pharma Co., Ltd. (CN) | 2015-05-27 | — | — | EP | disclosed |
| EP-2342175-B1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NITROGENIX INC (VG) | 2015-05-27 | — | — | EP | disclosed |
| US-20150141399-A1 | MEK Inhibitors And Methods Of Their Use | EXELIXIS INC (US) | 2015-05-21 | — | — | US | disclosed |
| WO-2015073342-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150125741-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, SECONDARY BATTERY, BATTERY PACK, ELECTRIC VEHICLE, ELECTRIC POWER STORAGE SYSTEM, ELECTRIC POWER TOOL, AND ELECTRONIC APPARATUS | TOHOKU MURATA MANUFACTURING CO., LTD. (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20150125741-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, SECONDARY BATTERY, BATTERY PACK, ELECTRIC VEHICLE, ELECTRIC POWER STORAGE SYSTEM, ELECTRIC POWER TOOL, AND ELECTRONIC APPARATUS | TOHOKU MURATA MANUFACTURING CO., LTD. (JP) | 2015-05-07 | — | — | US | disclosed |
| EP-2865666-A1 | HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2015-04-29 | — | — | EP | disclosed |
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20150097904-A1 | LAMINATE PRODUCING METHOD | MIMAKI ENGINEERING CO., LTD. (JP) | 2015-04-09 | — | — | US | disclosed |
| US-20150097904-A1 | LAMINATE PRODUCING METHOD | MIMAKI ENGINEERING CO., LTD. (JP) | 2015-04-09 | — | — | US | disclosed |
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| WO-2015018333-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2015-02-12 | — | — | WO | disclosed |
| US-20150038574-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| WO-2014200637-A1 | SYNTHESIS OF ISOHEXIDE DICARBAMATES AND DERIVATIVES THEREOF | ARCHER DANIELS MIDLAND COMPANY (US) | 2014-12-18 | — | — | WO | disclosed |
| US-8901137-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors | EXELIXIS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2793892-A1 | COMBINATION THERAPIES FOR TREATING HEMATOLOGIC MALIGNANCIES USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K/MTOR WITH BENDAMUSTINE AND/OR RITUXIMAB | Exelixis, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | SANOFI (FR) | 2014-10-09 | — | — | US | disclosed |
| EP-2785178-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20140296265-A1 | Method of Treating Lymphoma Using Pyridopyrimidinone Inhibitors of PI3K/mTOR | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
| US-8846739-B2 | TGR5 agonists | EXELIXIS PATENT COMPANY LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846674-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX, S.A. (FR) | 2014-09-30 | — | — | US | disclosed |
| WO-2014139388-A1 | NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140256782-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2014134127-A1 | CANNABINERGIC NITRATE ESTERS AND RELATED ANALOGS | NORTHEASTERN UNIVERSITY (US) | 2014-09-04 | — | — | WO | disclosed |
| US-8822136-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822136-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| WO-2014130608-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-08-28 | — | — | WO | disclosed |
| EP-2768307-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796258-B2 | Cyclic azabenzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| WO-2014111465-A1 | ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | SANOFI (FR) | 2014-07-24 | — | — | WO | disclosed |
| US-8785488-B2 | Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity | EXELIXIS PATENT COMPANY LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| WO-2014087113-A1 | COMPOUNDS BASED ON DIANHYDROHEXITOL AND CROSS-LINKABLE COMPOSITIONS COMPRISING SAID COMPOUNDS | ROQUETTE FRERES (FR) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014087112-A1 | CROSS-LINKABLE COMPOSITIONS BASED ON DIANHYDROHEXITOL COMPOUNDS | ROQUETTE FRERES (FR) | 2014-06-12 | — | — | WO | disclosed |
| EP-2139484-B9 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-20140155396-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155378-A9 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-05-29 | — | — | US | disclosed |
| EP-2139483-B9 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20140135374-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2730572-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | Sunshine Lake Pharma Co., Ltd (CN) | 2014-05-14 | — | — | EP | disclosed |
| EP-1663204-B1 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8710038-B2 | Pyrazole kinase modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2720539-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8697737-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| EP-2392565-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2701690-A1 | METHOD OF TREATING LYMPHOMA USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K/MTOR | Exelixis, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | FARBER MICHAEL (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2014031468-A1 | NOVEL BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031445-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031465-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031441-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031517-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031515-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2014022528-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014019186-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-06 | — | — | WO | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| WO-2014012360-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-01-23 | — | — | WO | disclosed |
| EP-2677869-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20130303505-A1 | TGR5 AGONISTS | EXELIXIS PATENT COMPANY LLC | 2013-11-14 | — | — | US | disclosed |
| EP-2392564-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-1611123-B1 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20130252940-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| EP-2139483-B1 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-1940839-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha | EXELIXIS INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8497284-B2 | C-met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2139484-B1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2612853-A1 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8481001-B2 | Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer | EXELIXIS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130172371-A1 | Methods of Treating Cancer Using Pyridopyrimidinone Inhibitors of PI3K and mTOR in Combination with Autophagy Inhibitors | EXELIXIS, INC (US) | 2013-07-04 | — | — | US | disclosed |
| EP-2609919-A2 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8476298-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2013096093-A1 | COMPOUNDS AS DGAT-1 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2013081642-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| US-20130123237-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2590654-A1 | COMBINATIONS OF KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Exelixis, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| WO-2013067306-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS FOR THE TREATMENT OF CHILDHOOD CANCERS | EXELIXIS, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013066461-A2 | RENEWABLE BIO-BASED (METH) ACRYLATED MONOMERS AS VINYL ESTER CROSS-LINKERS | PALMESE GIUSEPPE R (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130108960-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-20130108960-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| WO-2013058809-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-8426585-B2 | Compounds comprising a spiro-ring | Xi, Ning (US) | 2013-04-23 | — | — | US | disclosed |
| WO-2013056067-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF BASAL CELL CARCINOMA | EXELIXIS, INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| US-8372851-B2 | Pyrazolo pyrimidines as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8362002-B2 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2012174327-A1 | COMBINATION THERAPIES FOR TREATING HEMATOLOGIC MALIGNANCIES USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K/MTOR WITH BENDAMUSTINE AND/OR RITUXIMAB | EXELIXIS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012174064-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20120315247-A1 | COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2012-12-13 | — | — | US | disclosed |
| EP-2532657-A2 | Compounds and methods of use | Sunshine Lake Pharma Co., Ltd (CN) | 2012-12-12 | — | — | EP | disclosed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| EP-2527330-A1 | Inhibitors of the hedgehog pathway | Exelixis, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| WO-2012152438-A1 | PROCESS FOR THE PREPARATION OF NITRATE ACID ESTER OF ORGANIC COMPOUNDS | NICOX S.A. (FR) | 2012-11-15 | — | — | WO | disclosed |
| US-8308198-B2 | Water-based fluorescent ink, recorded image using the same, and judging method | CANON KABUSHIKI KAISHA (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8304409-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2012-11-06 | — | — | US | disclosed |
| WO-2012149308-A1 | METHOD OF TREATING LYMPHOMA USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K/MTOR | EXELIXIS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| EP-2515329-A1 | METHOD FOR PRODUCING ELECTRONIC DEVICE, ELECTRONIC DEVICE, METHOD FOR PRODUCING ELECTRONIC DEVICE PACKAGE, AND ELECTRONIC DEVICE PACKAGE | Sumitomo Bakelite Co., Ltd. (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-8293897-B2 | Compounds comprising a spiro-ring and methods of use | Xi, Ning (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2012134971-A2 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-2506298-A1 | PRODUCTION METHOD FOR ELECTRONIC DEVICE, ELECTRONIC DEVICE, PRODUCTION METHOD FOR ELECTRONIC DEVICE PACKAGE, AND ELECTRONIC DEVICE PACKAGE | Sumitomo Bakelite Company Limited (JP) | 2012-10-03 | — | — | EP | disclosed |
| US-20120245139-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS PATENT COMPANY LLC (US) | 2012-09-27 | — | — | US | disclosed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS PATENT COMPANY LLC (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120228782-A1 | METHOD FOR MANUFACTURING ELECTRONIC DEVICE, ELECTRONIC DEVICE, METHOD FOR MANUFACTURING ELECTRONIC DEVICE PACKAGE AND ELECTRONIC DEVICE PACKAGE | Sumitomo Bakelite Co, Ltd (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120228782-A1 | METHOD FOR MANUFACTURING ELECTRONIC DEVICE, ELECTRONIC DEVICE, METHOD FOR MANUFACTURING ELECTRONIC DEVICE PACKAGE AND ELECTRONIC DEVICE PACKAGE | Sumitomo Bakelite Co, Ltd (JP) | 2012-09-13 | — | — | US | disclosed |
| EP-1931670-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | EXELIXIS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2012116145-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2012-08-30 | — | — | WO | disclosed |
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2238143-B1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2012-08-15 | — | — | EP | disclosed |
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8232294-B2 | Amino ester derivatives, sailts thereof and methods of use | Xi, Ning (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120184523-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222256-B2 | Methods of using IGFIR and ABL kinase modulators | EXELIXIS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222277-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2012-07-17 | — | — | US | disclosed |
| EP-1678168-B1 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-8211929-B2 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| WO-2012065057-A2 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012065019-A2 | PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-8178570-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178532-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2442644-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-8163771-B2 | 11 β-HSD1 modulators | EXELIXIS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | EXELIXIS PATENT COMPANY LLC (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. | 2012-02-09 | — | — | US | disclosed |
| EP-1848719-B1 | [1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES | EXELIXIS INC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20120022065-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2409704-A2 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2408300-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd (CN) | 2012-01-25 | — | — | EP | disclosed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| WO-2012006552-A1 | COMBINATIONS OF KINASE INHIBITORS FOR THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8088762-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011155983-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2392565-A1 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392564-A1 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-8067414-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX S.A. (FR) | 2011-11-29 | — | — | US | disclosed |
| US-8067464-B2 | Compositions and methods using apocynin compounds and nitric oxide donors | NITROMED, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067436-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2388262-A1 | New biobased chiral compounds | Stichting Dutch Polymer Institute (NL) | 2011-11-23 | — | — | EP | disclosed |
| EP-1673085-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110263558-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-8044062-B2 | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha | EXELIXIS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110255073-A1 | POLYMERIZED FILMS WITH LINE TEXTURE OR FINGERPRINT TEXTURE | BASF SE (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110250255-A1 | DRUG COATED STENT WITH ENDOSOME-DISRUPTING CONJUGATE | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011119465-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110237608-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| EP-1948663-B1 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2364974-A1 | N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors | Exelixis, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110207712-A1 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use | EXELIXIS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011100319-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K AND MTOR IN COMBINATION WITH AUTOPHAGY INHIBITORS | EXELIXIS, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| EP-2210607-B1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | EXELIXIS INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110195935-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | BENOIT & COTE (CA) | 2011-08-11 | — | — | US | disclosed |
| EP-1841760-B1 | PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2011-08-10 | — | — | EP | disclosed |
| US-7994172-B2 | [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism | EXELIXIS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7989622-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-2213661-B1 | c-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7981408-B2 | Method of preserving food using antimicrobial packaging | BOSTON BRANDS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| EP-2342175-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | Nitrogenix Inc. (VG) | 2011-07-13 | — | — | EP | disclosed |
| US-7977345-B2 | c-MET modulators and method of use | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2340244-A1 | COMPOUNDS AND METHODS OF USE | Xi, Ning (US) | 2011-07-06 | — | — | EP | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2322523-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2320895-A2 | CDK MODULATORS | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20110097562-A1 | THERMALLY INSULATING FILMS AND LAMINATES | BASF SE (DE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098253-A1 | Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use | NICOX S.A. (IT) | 2011-04-28 | — | — | US | disclosed |
| EP-1934174-B1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS INC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-7915250-B2 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | EXELIXIS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2280966-A1 | AZABICYCLO [3.2.1]OCTYL DERIVATIVES AS 11 BETA-HSD1 MODULATORS | Exelixis, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-7883714-B2 | (2R)-2,3-bis(nitrooxy)propyl(2S)-2(6-methoxy(2-naphthyl)propanoate, used for treating inflammation, pain and fever; gastrointestinal disorders; wound healing agents; preventing gastrointestinal, renal and/or respiratory toxicities; side effect reduction; kits | NICOX S.A. (FR) | 2011-02-08 | — | — | US | disclosed |
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7872014-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7871539-B2 | Liquid crystal composition, liquid crystal element, reflective display material, light-controlling material, and method of preparing liquid crystal composition | FUJIFILM CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7871539-B2 | Liquid crystal composition, liquid crystal element, reflective display material, light-controlling material, and method of preparing liquid crystal composition | FUJIFILM CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. | 2011-01-06 | — | — | US | disclosed |
| US-7858670-B2 | Photosensitive inkjet ink | TOSHIBA TEC KABUSHIKI KAISHA (JP) | 2010-12-28 | — | — | US | disclosed |
| US-7858670-B2 | Photosensitive inkjet ink | TOSHIBA TEC KABUSHIKI KAISHA (JP) | 2010-12-28 | — | — | US | disclosed |
| WO-2010147653-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100311780-A1 | Nitric oxide amino acid ester compound, composition for increasing nitirc oxide levels and method of use | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-12-09 | — | — | US | disclosed |
| US-7846959-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7838023-B2 | Furoxan compounds, compositions and methods of use | NITROMED, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| WO-2010130840-A1 | TRIAZOLE/TETRAZOLE POLYMERS RESULTING FROM THE CYCLOADDITION OF FUNCTIONALIZED MONOMERS DERIVED FROM DIANHYDROHEXITOL, INTERMEDIATE COMPOUNDS, METHODS OF PREPARING SAME AND APPLICATIONS THEREOF | ROQUETTE FRERES (FR) | 2010-11-18 | — | — | WO | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7807716-B2 | Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-10-05 | — | — | US | disclosed |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100247796-A1 | ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100247796-A1 | ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| WO-2010111063-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | XI NING (US) | 2010-09-30 | — | — | WO | disclosed |
| EP-2233542-A1 | Active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | Fujifilm Corporation (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-7803839-B2 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100239576-A1 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2226367-A1 | Active energy ray-curable ink composition, inkjet recording method and printed material | Fujifilm Corporation (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7772278-B2 | Nitrosated and nitrosylated prostaglandins, compositions and methods of use | NITROMED, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2213661-A1 | c-Met Modulators and Methods of Use | Exelixis Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| EP-2210607-A1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | Exelixis Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7754772-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX, S.A. (FR) | 2010-07-13 | — | — | US | disclosed |
| WO-2010074746-A1 | METHODS OF USE FOR OPSIN BINDING LIGANDS | BIKAM PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| EP-2199294-A1 | New stereospecific method for the preparation of dioxa bicyclooctane nitrate compounds | LACER, S.A. (ES) | 2010-06-23 | — | — | EP | disclosed |
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100137291-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NICOX SA (FR) | 2010-06-03 | — | — | US | disclosed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100130488-A1 | Pyrazolo-Pyrimidines as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-7708989-B2 | Methods of treating vascular diseases characterized by nitric oxide insufficiency | NITROMED, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | EXELIXIS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2010045095-A1 | COMPOUNDS AND METHODS OF USE | XI NING (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093727-A1 | COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2010-04-15 | — | — | US | disclosed |
| US-20100093671-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NICOX SA (FR) | 2010-04-15 | — | — | US | disclosed |
| US-20100093708-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NICOX SA (FR) | 2010-04-15 | — | — | US | disclosed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | disclosed |
| WO-2010034118-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-04-01 | — | — | WO | disclosed |
| US-20100076043-A1 | NITRIC OXIDE AMINO ACID ESTER COMPOUND, COMPOSITIONS FOR INCREASING NITRIC OXIDE LEVELS AND METHOD OF USE | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100068267-A1 | COMPOSITIONS FOR TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY | NITROMED, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20100026771-A1 | INKJET RECORDING METHOD, INKJET RECORDING SYSTEM, AND PRINTED MATERIAL | FUJIFILM CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2149457-A2 | Inkjet recording method, inkjet recording system, and printed material | Fujifilm Corporation (JP) | 2010-02-03 | — | — | EP | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-2139483-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | Exelixis, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2139484-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | Exelixis, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2134695-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | Exelixis, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090306081-A1 | Solid Dosage Formulations of Hydralazine Compounds and Nitric Oxide Donor Compounds | ARBOR PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306027-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM | NITOMED, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-7626031-B2 | 5-[(1-Ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; antiproliferative agents; modulating cell differentiation,migration, and chemoinvasion; endothelial growth factor-modulated diseases; antiarthritic agents; graft versus host diseases | SYMPHONY EVOLUTION, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090253662-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM | NITROMED, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7595313-B2 | Nitric oxide donating diuretic compounds, compositions and methods of use | NICOX, S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009114173-A1 | AZABICYCLO [3. 2. I] OCTYL DERIVATIVES AS 11 BETA-HSDL MODULATORS | EXELIXIS, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090232828-A1 | Methods of Using IGFIR and ABL Kinase Modulators | EXELIXIS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-7589124-B2 | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use | NICOX, S.A. (FR) | 2009-09-15 | — | — | US | disclosed |
| US-20090226501-A1 | DRUG COATED STENT WITH ENDOSOME-DISRUPTING CONJUGATE | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090226407-A9 | METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY | LOSCALZO JOSEPH | 2009-09-10 | — | — | US | disclosed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-1797072-A4 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090203653-A1 | Compositions and Methods Using Apocynin Compounds and Nitric Oxide Donors | NITROMED, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090192128-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF BETA 1 ADRENERGIC RECEPTOR GLY389ARG POLYMORPHISM | NITROMED INC. (US) | 2009-07-30 | — | — | US | disclosed |
| EP-1581309-A4 | KINASE MODULATORS | EXELIXIS INC (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1406608-B1 | NITROSATED AND NITROSYLATED NEBIVOLOL AND ITS METABOLITES, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| EP-1244455-B1 | METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY | NITROMED INC (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1874759-A4 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-7556824-B2 | Transdermal patch composition for treating vascular diseases characterized by nitric oxide insufficiency | NITROMED, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-2074103-A1 | 6-PHENYLPYRIMIDINONES AS PIM MODULATORS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009076272-A2 | DRUG COATED STENT WITH ENDOSOME-DISRUPTING CONJUGATE | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-1773826-A4 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7537785-B2 | Composition for treating vascular diseases characterized by nitric oxide insufficiency | NITROMED, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20090131342-A1 | Nitrosated and/or nitrosylated compounds, compositions and methods of use | NITROMED, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090118293-A1 | METHODS FOR REDUCING HOSPITALIZATIONS RELATED TO HEART FAILURE | NITROMED, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118294-A1 | COMPOSITIONS AND METHODS RELATED TO HEART FAILURE | NITROMED, INC. | 2009-05-07 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090099139-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| EP-1943361-A4 | THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM | NITROMED INC (US) | 2009-04-15 | — | — | EP | disclosed |
| EP-2043651-A2 | METHODS OF USING IGF1R AND ABL KINASE MODULATORS | Exelixis, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20090088366-A1 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090078889-A1 | Water-Based Fluorescent Ink, Recorded Image Using The Same, and Judging Method | CANON KABUSHIKI KAISHA (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1670459-A4 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20090075956-A1 | Genetic Risk Assessment in Heart Failure: Impact of the Genetic Variation of NOS3 | NITROMED, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1648455-A4 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090053328-A1 | Nitric Oxide Enhancing Glutamic Acid Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054381-A1 | METHODS FOR TREATING RESPIRATORY DISORDERS | NITROMED, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1668008-A4 | NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC. (US) | 2009-02-19 | — | — | US | disclosed |
| EP-2024337-A1 | SOLID DOSAGE FORMULATIONS OF HYDRALAZINE COMPOUNDS | Nitromed, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20090042819-A1 | Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use | NITROMED, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090018091-A1 | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| EP-2010169-A2 | THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM | Nitromed, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7473720-B2 | Photosensitive inkjet ink | TOSHIBA TEC KABUSHIKI KAISHA (JP) | 2009-01-06 | — | — | US | disclosed |
| US-7473437-B2 | Method of forming fluorescent image, fluorescent image, and ink-jet recording method | CANON KABUSHIKI KAISHA (JP) | 2009-01-06 | — | — | US | disclosed |
| US-20090005350-A1 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| EP-2007705-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7464965-B2 | Water-based fluorescent ink, recorded image using the same, and judging method | CANON KABUSHIKI KAISHA (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | NICOX S.A. (FR) | 2008-12-11 | — | — | US | disclosed |
| EP-1673085-A4 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20080300292-A1 | Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders | NITROMED, INC (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080293724-A1 | Methods Using Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080292817-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, REFLECTIVE DISPLAY MATERIAL, LIGHT-CONTROLLING MATERIAL, AND METHOD OF PREPARING LIQUID CRYSTAL COMPOSITION | FUJIFILM CORPORATON (JP) | 2008-11-27 | — | — | US | disclosed |
| US-20080292817-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, REFLECTIVE DISPLAY MATERIAL, LIGHT-CONTROLLING MATERIAL, AND METHOD OF PREPARING LIQUID CRYSTAL COMPOSITION | FUJIFILM CORPORATON (JP) | 2008-11-27 | — | — | US | disclosed |
| US-20080291389-A1 | Elliptically Polarizing Plate and Image Display Apparatus Using the Same | NITTO DENKO CORPORATION (JP) | 2008-11-27 | — | — | US | disclosed |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293702-A1 | Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-7455400-B2 | Aqueous fluorescent ink, image recording method and recorded image | CANON KABUSHIKI KAISHA (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-7449595-B2 | for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions | NITROMED, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2008133955-A1 | 6-PHENYLPYRIMIDINONES AS PIM MODULATORS | EXELIXIS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275093-A1 | Diuretic Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080268014-A1 | Furoxan Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1984010-A2 | METHODS USING HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE | Nitromed, Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1692107-A4 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7443900-B2 | Laser gain medium for solid state dye lasers | BASF AKTIENGESELLSCHAFT (DE) | 2008-10-28 | — | — | US | disclosed |
| US-7442802-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008124161-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-1979329-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20080249079-A1 | N2-{[3-(1-methylethyl)isoxazol-5-yl]methyl}-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methylpiperidin-3-yl)oxy]pyrimidine-2,4-diamine; IGF1R modulators; Abl mutant inhibitors; antiproliferative agents; to modulate cellular activities like differentiation, programmed cell death, migration, chemoinvas | EXELIXIS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-7432285-B2 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1678168-A4 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1971340-A2 | NITRIC OXIDE ENHANCING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20080226752-A1 | KITS OF HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE AND/OR ISOSORBIDE MONONITRATE | NITROMED, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| EP-1968584-A2 | NITRIC OXIDE ENHANCING GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| US-7425525-B2 | Washing solution for inkjet printer head and washing method using the solution | TOSHIBA TEC KABUSHIKI KAISHA (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425525-B2 | Washing solution for inkjet printer head and washing method using the solution | TOSHIBA TEC KABUSHIKI KAISHA (JP) | 2008-09-16 | — | — | US | disclosed |
| EP-1954685-A2 | FUROXAN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1663204-A4 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| EP-1948617-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1948663-A2 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1945030-A2 | THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF BETA 1 ADRENERGIC RECEPTOR GLY389ARG POLYMORPHISM | Nitromed, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1610774-A4 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1942909-A2 | METHODS FOR TREATING RESPIRATORY DISORDERS | Nitromed, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1943361-A2 | THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM | Nitromed, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1339812-B1 | CHIRAL PHOTOISOMERIZABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| EP-1940839-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha | Exelixis, Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1611123-A4 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1934174-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1931670-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | Exelixis, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1931645-A2 | N- (3-AMINO-QUINOXALIN-2-YL) -SULFONAMIDE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Exelixis, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| US-7384976-B2 | Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use | NITROMED, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1814535-A4 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISORDERS | NITROMED INC (US) | 2008-06-04 | — | — | EP | disclosed |
| EP-1922069-A2 | NITRIC OXIDE ENHANCING ANGIOTENSIN II ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7375145-B2 | capable of overcoming the problems such as poor cation polymerizing reaction and solvent resistance which are particularly accompanied with the conventional photosensitive inkjet ink containing, as a main component, a vinyl ether compound | TOSHIBA TEC KABUSHIKI KAISHA (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375145-B2 | capable of overcoming the problems such as poor cation polymerizing reaction and solvent resistance which are particularly accompanied with the conventional photosensitive inkjet ink containing, as a main component, a vinyl ether compound | TOSHIBA TEC KABUSHIKI KAISHA (JP) | 2008-05-20 | — | — | US | disclosed |
| EP-1915157-A2 | NITRIC OXIDE ENHANCING ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| EP-1109542-A4 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-03-26 | — | — | EP | disclosed |
| US-7345053-B2 | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use | NITROMED, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1667643-A4 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1889845-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SmithKline Beecham P.L.C. (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1539729-A4 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7332505-B2 | Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1883614-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1542972-A4 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1877374-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | NITROMED, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009488-A1 | Raf Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2008005538-A2 | METHODS OF USING IGF1R AND ABL KINASE MODULATORS | EXELIXIS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-1874759-A1 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1865770-A2 | THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF NOS3 | Nitromed, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1861093-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7303620-B2 | Water-based ink, and image formation method and recorded image using the ink | CANON KABUSHIKI KAISHA (JP) | 2007-12-04 | — | — | US | disclosed |
| WO-2007136626-A1 | SOLID DOSAGE FORMULATIONS OF HYDRALAZINE COMPOUNDS | NITROMED, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1858863-A1 | CARDIOVASCULAR COMPOUNDS COMPRISING NITRIC OXIDE ENHANCING GROUPS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1858525-A2 | ORGANIC NITRIC OXIDE DONOR SALTS OF ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20070270520-A1 | Capable of overcoming the problems such as poor cation polymerizing reaction and solvent resistance which are particularly accompanied with the conventional photosensitive inkjet ink containing, as a main component, a vinyl ether compound | RISO TECHNOLOGIES CORPORATION (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-1855688-A2 | NITRIC OXIDE ENHANCING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1301500-B1 | NITROSATED AND NITROSYLATED TAXANES, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007126609-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007123818-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1848719-A1 | [1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-7288297-B2 | Optical compensation plate, polarizing plate using the same and image display apparatus using the same | NITTO DENKO CORPORATION (JP) | 2007-10-30 | — | — | US | disclosed |
| WO-2007120555-A2 | ASSESSMENT OF HEART FAILURE RISK USING GENETIC ASSESSMENT OF G-PROTEIN BETA-3 SUBUNIT POLYMORPHISM | NITROMED, INC, (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1846380-A1 | CARDIOVASCULAR COMPOUNDS COMPRISING HETEROCYCLIC NITRIC OXIDE DONOR GROUP COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-7282519-B2 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070238740-A1 | Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use | NITROMED, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070238735-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITRODMED, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| EP-1841760-A2 | PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHOD OF USE | Exelixis, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7270855-B2 | Optical film, method for manufacturing the same, and phase difference film and polarizing plate using the same | NITTO DENKO CORPORATION (JP) | 2007-09-18 | — | — | US | disclosed |
| US-7267716-B2 | A water-soluble substance crystallizes as the water content decreases from an initial value; a coloring material is dispersed and the water-soluble substance is dissolved in the aqueous medium and the dispersed coloring material aggregates around a crystal of the water-soluble substance as a core. | CANON KABUSHIKI KAISHA (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
| EP-1828155-A2 | DIURETIC COMPOUNDS COMPRISING HETEROCYCLIC NITRIC OXIDE DONOR GROUPS,COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7264748-B2 | Aqueous mini-emulsions which are stable in storage and based on cholesteric mixtures | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-04 | — | — | US | disclosed |
| US-20070202437-A1 | PHOTOSENSITIVE COMPOSITION | TOSHIBA TEC KABUSHIKI KAISHA (JP) | 2007-08-30 | — | — | US | disclosed |
| WO-2007097951-A2 | METHODS USING HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE | NITROMED, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070191377-A1 | Methods for treating blood disorders with nitric oxide donor compounds | NITROMED, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7256205-B2 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| WO-2007089768-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EXELIXIS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070185224-A1 | PHOTOSENSITIVE INKJET INK | KABUSHIKI KAISHA TOSHIBA (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185224-A1 | PHOTOSENSITIVE INKJET INK | KABUSHIKI KAISHA TOSHIBA (JP) | 2007-08-09 | — | — | US | disclosed |
| EP-1814535-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISORDERS | Nitromed, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7252785-B2 | Composition of a radiation-absorbing tert-alkylphenoxy-substituted polycyclic ccmpound and a curable IR-reflecting component of achiral nematic polymerizable monomer, a chiral polymerizable monomer, a cholesteric polymerizable monomer, and a cholesteric polymer in a polymerizable diluent | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-07 | — | — | US | disclosed |
| WO-2007086884-A2 | ORGANIC NITRIC OXIDE DONOR SALTS OF ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179150-A1 | NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179195-A1 | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| EP-1678121-A4 | TAO KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7244753-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| WO-2007075542-A2 | NITRIC OXIDE ENHANCING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075541-A2 | NITRIC OXIDE ENHANCING GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070155734-A1 | Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1539679-A4 | OXIME AND/OR HYDRAZONE CONTAINING NITROSATED AND/OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2007-07-04 | — | — | EP | disclosed |
| US-7238814-B2 | Compositions of S-nitrosothiols and methods of use | NITROMED, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1538150-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2007-06-27 | — | — | EP | disclosed |
| US-7235237-B2 | Methods of treating vascular diseases characterized by nitric oxide insufficiency | NITROMED, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235283-B2 | Optical compensation plate and deflecting plate using the same | NITTO DENKO CORPORATION (JP) | 2007-06-26 | — | — | US | disclosed |
| EP-1797072-A2 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007059311-A2 | FUROXAN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-7220301-B2 | Ink, ink-jet recording process, recorded article, recording unit, ink cartridge, ink-jet recording apparatus fluorescence enhancing method and method of elongating life time of fluorescence | CANON KABUSHIKI KAISHA (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220749-B2 | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20070112067-A1 | Nitrosated and nitrosylated prostaglandins, compositions and methods of use | NITROMED, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070101898-A1 | Inkjet ink | AKIYAMA RYOZO | 2007-05-10 | — | — | US | disclosed |
| EP-1778267-A2 | COMPOSITIONS AND METHODS RELATED TO HEART FAILURE | Nitromed, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7211590-B2 | Nitrosated proton pump inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211598-B2 | Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| WO-2007048064-A2 | AMINO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007048066-A2 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007048065-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007044813-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044515-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044729-A2 | N- (3-AMINO-QUINOXALIN-2-YL) -SULFONAMIDE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044698-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1773826-A2 | C-MET MODULATORS AND METHOD OF USE | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007041681-A2 | METHODS FOR TREATING RESPIRATORY DISORDERS | NITROMED, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041680-A2 | THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF BETA 1 ADRENERGIC RECEPTOR GLY389ARG POLYMORPHISM | NITROMED, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041676-A2 | THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM | NITROMED, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1539134-A4 | NITROSATED AND/OR NITROSYLATED CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20070060571-A1 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070034114-A1 | Can improve both fluorescence properties and water resistance of the image, which has been difficult with conventional fluorescent coloring materials, and can contain a large amount of a fluorescent coloring material, and in addition, improved sticking resistance and reliability | CANON KABUSHIKI KAISHA (JP) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019448-A2 | NITRIC OXIDE ENHANCING ANGIOTENSIN II ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1751124-A2 | RAF MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1750727-A2 | KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7176238-B1 | Nitrostated and nitrosylated prostaglandins, compositions and methods of use | NITROMED INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20070032515-A1 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| WO-2007016095-A2 | CYCLOOXYGENASE-2 SELECTIVE INHIBITOR COMPOUNDS COMPRISING NITRIC OXIDE ENHANCING GROUPS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016677-A2 | NITRIC OXIDE ENHANCING ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| WO-2007016136-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| EP-1673384-A4 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1746882-A2 | METHODS FOR TREATING BLOOD DISORDERS WITH NITRIC OXIDE DONOR COMPOUNDS | Nitromed, Inc. (US) | 2007-01-31 | — | — | EP | disclosed |
| US-7166618-B2 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7163958-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20070010571-A1 | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| US-20070004788-A1 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060293342-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2006-12-28 | — | — | US | disclosed |
| EP-1730128-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006127591-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-7138430-B2 | Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use | NITROMED, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1718286-A2 | NITROSATED AND/OR NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| US-7129251-B2 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| WO-2006110601-A2 | THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF NOS3 | NITROMED, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-7122227-B2 | Electrooptics; liquid crystal display | MERCK PATENT GESELLSCHAFT (DE) | 2006-10-17 | — | — | US | disclosed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| WO-2006108059-A1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006102071-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006099058-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099416-A1 | 2-METHYL INDOLE CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006093864-A1 | CARDIOVASCULAR COMPOUNDS COMPRISING NITRIC OXIDE ENHANCING GROUPS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| EP-1406609-B1 | SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1534278-A4 | NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060194861-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| WO-2006091716-A2 | NITRIC OXIDE ENHANCING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060189603-A1 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-1692107-A2 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| US-7087630-B2 | Cyclooxygenase 2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| WO-2006078995-A1 | CARDIOVASCULAR COMPOUNDS COMPRISING HETEROCYCLIC NITRIC OXIDE DONOR GROUP COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006074057-A2 | PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-1678121-A2 | TAO KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1678168-A2 | P70S6 KINASE MODULATORS AND METHOD OF USE | Exelixis, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006071819-A1 | [1H-PYRAZOLO[3, 4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THEORONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| EP-1673384-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1670459-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1668008-A2 | NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1667643-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060122171-A1 | Kinase modulators | SYMPHONY EVOLUTION, INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1663204-A2 | C-KIT MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006055542-A2 | DIURETIC COMPOUNDS COMPRISING HETEROCYCLIC NITRIC OXIDE DONOR GROUPS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1584634-A4 | POLYMERIC COMPOUND FOR PHOTORESIST AND RESIN COMPOSITION FOR PHOTORESIST | DAICEL CHEM (JP) | 2006-05-24 | — | — | EP | disclosed |
| WO-2006052899-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISORDERS | NITROMED, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-1648455-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-7033726-B2 | Photoresist polymeric compound and photoresist resin composition | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-04-25 | — | — | US | disclosed |
| US-7033726-B2 | Photoresist polymeric compound and photoresist resin composition | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-04-25 | — | — | US | disclosed |
| WO-2006041855-A2 | COMPOSITIONS AND METHODS USING APOCYNIN COMPOUNDS AND NITRIC OXIDE DONORS | NITROMED, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006033943-A2 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060058480-A1 | Polymerizable monomer polymeric compound resin compositions for photoresist and method for producing semiconductor | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1109543-A4 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2006020244-A2 | COMPOSITIONS AND METHODS RELATED TO HEART FAILURE | NITROMED, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006014325-A2 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060014828-A1 | Compositions and methods related to heart failure | NITROMED, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-20060014829-A1 | Methods for reducing hospitalizations related to heart failure | NITROMED, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| EP-1497268-A4 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20060009513-A1 | Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use | NITROMED, INC. (US) | 2006-01-12 | — | — | US | disclosed |
| US-20060009431-A1 | Nitrosated and nitrosylated compounds, compositions and methods use | NITROMED, INC. (US) | 2006-01-12 | — | — | US | disclosed |
| EP-1611123-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1610774-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1608373-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005117909-A2 | KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1603933-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050271780-A1 | Method of preserving food using antimicrobial packaging | BOSTON BRANDS, INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005112932-A2 | RAF MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005107384-A2 | METHODS FOR TREATING BLOOD DISORDERS WITH NITRIC OXIDE DONOR COMPOUNDS | NITROMED, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050250758-A1 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-11-10 | — | — | US | disclosed |
| EP-1140066-A4 | NITROSATED AND NITROSYLATED H2 RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005097765-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-1584634-A1 | POLYMERIC COMPOUND FOR PHOTORESIST AND RESIN COMPOSITION FOR PHOTORESIST | Daicel Chemical Industries, Ltd. (JP) | 2005-10-12 | — | — | EP | disclosed |
| EP-1584634-A1 | POLYMERIC COMPOUND FOR PHOTORESIST AND RESIN COMPOSITION FOR PHOTORESIST | Daicel Chemical Industries, Ltd. (JP) | 2005-10-12 | — | — | EP | disclosed |
| US-20050222243-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| EP-1581309-A2 | KINASE MODULATORS | Exelixis, Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005087742-A1 | METABOLIC KINASE MODULATORS AND METHODS OF USE AS PESTICIDES | EXELIXIS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050209266-A1 | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| US-6936627-B2 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050187222-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds | NITROMED, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| EP-1534683-A4 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6930113-B2 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2005-08-16 | — | — | US | disclosed |
| WO-2005070006-A2 | NITROSATED AND/OR NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005060603-A2 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| EP-1542972-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1539729-A2 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539134-A2 | NITROSATED AND/OR NITROSYLATED CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539679-A2 | OXIME AND/OR HYDRAZONE CONTAINING NITROSATED AND/OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1538150-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-08 | — | — | EP | disclosed |
| EP-1534278-A2 | NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1351959-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-01 | — | — | EP | disclosed |
| EP-1534683-A2 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-6900345-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-05-31 | — | — | US | disclosed |
| EP-1337283-A4 | METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY | NITROMED INC (US) | 2005-05-18 | — | — | EP | disclosed |
| WO-2005040355-A2 | TAO KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005039506-A2 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050096357-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. | 2005-05-05 | — | — | US | disclosed |
| EP-1284653-A4 | INFRARED THERMOGRAPHY AND METHODS OF USE | NITROMED INC (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-1154771-A4 | NITROSATED AND NITROSYLATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2005-04-20 | — | — | EP | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030135-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-6869973-B2 | Compounds that donate, transfer, or release nitric oxide, or induce the production of endogenous nitric oxide or endothelium-derived relaxing factor or is a substrate for nitric oxide synthase | NITROMED, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-20050059665-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005023183-A2 | NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023182-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005020921-A2 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005018561-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1126838-A4 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2005-02-16 | — | — | EP | disclosed |
| US-6852739-B1 | Methods using proton pump inhibitors and nitric oxide donors | NITROMED INC. (US) | 2005-02-08 | — | — | US | disclosed |
| WO-2005009389-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050014087-A1 | Photoresist polymeric compound and photoresist resin composition | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| US-20050014087-A1 | Photoresist polymeric compound and photoresist resin composition | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1497268-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040266828-A1 | Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2004-12-30 | — | — | US | disclosed |
| US-6825185-B2 | IMPROVING THE CARDIOVASCULAR PROFILE OF A COX-2 SELECTIVE INHIBITOR BY ADMINISTERING WITH 3-HYDROXY-3- METHYLGLUTARYL COENZYME A, AN ANTIPLATELET AGENT, A THROMBIN INHIBITOR OR A THROMBOXANE INHIBITOR | NITROMED, INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1246621-A4 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-2004098538-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004091480-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092196-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-1406608-A4 | NITROSATED AND NITROSYLATED NEBIVOLOL AND ITS METABOLITES, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040204371-A1 | for ADMINISTERING TO THE BLACK PATIENT FOR IMPROVING OXYGEN CONSUMPTION TO PREVENT HEART FAILURE, A HYDRALAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT AND AT LEAST ONE ISOBORIDE DINITRATE OR ISOBORIDE MONONITRATE | NITROMED, INC. (US) | 2004-10-14 | — | — | US | disclosed |
| WO-2004083235-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-6784177-B2 | ADMINISTERING TO THE BLACK PATIENT FOR IMPROVING OXYGEN CONSUMPTION TO PREVENT HEART FAILURE, A HYDRALAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT AND AT LEAST ONE ISOBORIDE DINITRATE OR ISOBORIDE MONONITRATE | NITRO MED, INC. | 2004-08-31 | — | — | US | disclosed |
| US-20040162243-A1 | Compositions of S-nitrosothiols and methods of use | NITROMED, INC. | 2004-08-19 | — | — | US | disclosed |
| EP-1212053-A4 | METHODS OF TREATING AND PREVENTING CONGESTIVE HEART FAILURE WITH HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE | NITROMED INC (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2004060283-A2 | NITROSATED AND NITROSYLATED RAPAMYCIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| US-6762202-B2 | Infrared thermography and methods of use | NITROMED, INC. | 2004-07-13 | — | — | US | disclosed |
| US-20040132805-A1 | Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use | NITROMED, INC. | 2004-07-08 | — | — | US | disclosed |
| US-20040116431-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2004-06-17 | — | — | US | disclosed |
| WO-2004050681-A2 | KINASE MODULATORS | EXELIXIS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040105850-A1 | Methods of treating vascular diseases characterized by nitric oxide insufficiency | ARBOR PHARMACEUTICALS, LLC | 2004-06-03 | — | — | US | disclosed |
| JP-2004155874-A | POLYMER COMPOUND FOR PHOTORESIST AND RESIN COMPOSITION FOR PHOTORESIST | DAICEL CHEM IND LTD | 2004-06-03 | — | — | JP | disclosed |
| WO-2004041881-A1 | POLYMERIC COMPOUND FOR PHOTORESIST AND RESIN COMPOSITION FOR PHOTORESIST | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2004-05-21 | — | — | WO | disclosed |
| US-20040087591-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | GARVEY DAVID S (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040087510-A1 | Cardiovascular diseases and disorders; sustained delivery of nitric oxide | NITROMED, INC. (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040081642-A1 | Methods of treating vascular diseases characterized by nitric oxide insufficiency related applications | ARBOR PHARMACEUTICALS, LLC | 2004-04-29 | — | — | US | disclosed |
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-04-15 | — | — | US | disclosed |
| US-20040072899-A1 | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use | NICOX S.A. (FR) | 2004-04-15 | — | — | US | disclosed |
| US-20040071766-A1 | Methods of treating vascular diseases characterized by nitric oxide insufficiency | ARBOR PHARMACEUTICALS, LLC | 2004-04-15 | — | — | US | disclosed |
| EP-1406608-A2 | NITROSATED AND NITROSYLATED NEBIVOLOL AND ITS METABOLITES, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1406609-A2 | SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1406609-A4 | SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1301500-A4 | NITROSATED AND NITROSYLATED TAXANES, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2004024186-A2 | TREATMENT OF CYCLOOXYGENASE-3 MEDIATED DISEASES AND DISORDERS | NITROMED, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20040053985-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-03-18 | — | — | US | disclosed |
| US-6706724-B2 | ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; ANALGESICS; ANTIPYRETIC AGENT | NITROMED, INC. | 2004-03-16 | — | — | US | disclosed |
| US-6693122-B2 | FOR THERAPY OF CARDIOVASCULAR DISORDER, CEREBROVASCULAR DISORDER, HYPERTENSION, ASTHMA, BALDNESS, URINARY INCONTINENCE, EPILEPSY, SLEEP DISORDER, GASTROINTESTINAL DISORDER, MIGRAINE, IRRITABLE BOWEL SYNDROME, SEXUAL DISORDER | NITROMED, INC. | 2004-02-17 | — | — | US | disclosed |
| WO-2004012686-A2 | NITROSATED AND/OR NITROSYLATED URSODEOXYCHOLIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-20040026660-A1 | Chiral photoisomerizable compounds | MERCK PATENT GMBH (DE) | 2004-02-12 | — | — | US | disclosed |
| WO-2004012659-A2 | NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-20040024059-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| US-20040024014-A1 | Nitrosated proton pump inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2004-02-05 | — | — | US | disclosed |
| WO-2004010945-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040023967-A1 | Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate | ARBOR PHARMACEUTICALS, LLC | 2004-02-05 | — | — | US | disclosed |
| WO-2004004648-A2 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004002420-A2 | OXIME AND/OR HYDRAZONE CONTAINING NITROSATED AND/OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002409-A2 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20040005306-A1 | Methods of treating vascular diseases characterized by nitric oxide insufficiency | ARBOR PHARMACEUTICALS, LLC | 2004-01-08 | — | — | US | disclosed |
| US-20040006133-A1 | Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003103602-A2 | NITROSATED AND/OR NITROSYLATED CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-6656966-B2 | Taxane containing nitroso (NO) group, or at least one NO and NO2 (nitro) group; treating cardiovascular disease | NITROMED, INC. | 2003-12-02 | — | — | US | disclosed |
| US-20030220228-A1 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NICOX S.A. (FR) | 2003-11-27 | — | — | US | disclosed |
| US-6649629-B2 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | NITROMED, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030207919-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2003-11-06 | — | — | US | disclosed |
| US-20030203915-A1 | Nitric oxide donors, compositions and methods of use related applications | NICOX S.A. (FR) | 2003-10-30 | — | — | US | disclosed |
| WO-2003086282-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-6635273-B1 | Antioxidant and at least one of isosorbide dinitrate and isosorbide mononitrate | TRUSTEES OF BOSTON UNIVERSITY | 2003-10-21 | — | — | US | disclosed |
| EP-1351959-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-10-15 | — | — | EP | disclosed |
| EP-1339812-A1 | CHIRAL PHOTOISOMERIZABLE COMPOUNDS | MERCK PATENT GmbH (DE) | 2003-09-03 | — | — | EP | disclosed |
| EP-1337283-A1 | METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY | Nitromed, Inc. (US) | 2003-08-27 | — | — | EP | disclosed |
| US-6593347-B2 | Especially a nitrosated and/or nitrosylated arylpropionic acid, arylacetic acid, enolic anilide or an oxicam | NITROMED, INC. | 2003-07-15 | — | — | US | disclosed |
| US-6552047-B2 | For therapy and prophylaxis of gastrointestinal disorders; inflammations, viral infections, multiple sclerosis; decreasing the recurrence of ulcers; facilitating ulcer healing | NITROMED, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1301500-A1 | NITROSATED AND NITROSYLATED TAXANES, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030060492-A1 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | CHIA-EN LIN. | 2003-03-27 | — | — | US | disclosed |
| US-20030050305-A1 | Thromboxane inhibitors, compositions and methods of use | NITROMED, INC. | 2003-03-13 | — | — | US | disclosed |
| EP-1284653-A2 | INFRARED THERMOGRAPHY AND METHODS OF USE | Nitromed, Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20030023087-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | GARVEY DAVID S (US) | 2003-01-30 | — | — | US | disclosed |
| US-20020183366-A1 | Cyclooxygenase-2 inhibitors, compositions and methods of use | NICOX S.A. (FR) | 2002-12-05 | — | — | US | disclosed |
| WO-2002087508-A2 | NITROSATED AND NITROSYLATED NEBIVOLOL AND ITS METABOLITES, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| US-6469065-B1 | COMPOUND THAT DONATES, TRANSFERS OR RELEASES NITRIC OXIDE, ELEVATES ENDOGENOUS LEVELS OF NITRIC OXIDE | NITROMED, INC. | 2002-10-22 | — | — | US | disclosed |
| EP-1246621-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-6462044-B2 | THERAPY FOR SEXUAL DISORDERS | NITROMED, INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020143188-A1 | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use | GARVEY DAVID S (US) | 2002-10-03 | — | — | US | disclosed |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | GARVEY DAVID S (US) | 2002-10-03 | — | — | US | disclosed |
| US-20020119977-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications | NICOX S.A. (FR) | 2002-08-29 | — | — | US | disclosed |
| WO-2002060378-A2 | SUBSTITUTED ARYL COMPOUNDS AS CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-6417207-B1 | POTASSIUM CHANNEL ACTIVATOR FOR CARDIOVASCULAR DISORDERS | NITROMED, INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020077343-A1 | H2 RECEPTOR ANTAGONIST COMPOUNDS IN COMBINATION WITH NITRIC OXIDE DONORS, COMPOSTIONS AND METHODS OF USE | NICOX S.A. (FR) | 2002-06-20 | — | — | US | disclosed |
| EP-1212053-A1 | METHODS OF TREATING AND PREVENTING CONGESTIVE HEART FAILURE WITH HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE | Nitromed, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2002040614-A1 | CHIRAL PHOTOISOMERIZABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2002-05-23 | — | — | WO | disclosed |
| US-20020051754-A1 | Anti-microbial packaging polymer and its method of use | BOSTON BRANDS, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002034303-A1 | METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY | NITROMED, INC. (US) | 2002-05-02 | — | — | WO | disclosed |
| WO-2002030929-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
| US-20020019405-A1 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use | GARVEY DAVID S (US) | 2002-02-14 | — | — | US | disclosed |
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NICOX S.A. (FR) | 2002-02-07 | — | — | US | disclosed |
| US-20020010146-A1 | Nitrosated and nitrosylated taxanes, compositions and methods of use | ARBOR PHARMACEUTICALS, LLC | 2002-01-24 | — | — | US | disclosed |
| WO-2001098286-A1 | NITROSATED AND NITROSYLATED TAXANES, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| US-6331543-B1 | TREATING SEXUAL DYSFUNCTION | NITROMED, INC. | 2001-12-18 | — | — | US | disclosed |
| WO-2001089519-A1 | THROMBOXANE INHIBITORS, COMPOSITIONS AND METHODS OF USE RELATED APPLICATIONS | NITROMED, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| US-20010046471-A1 | Infrared thermograpy and methods of use | NICOX S.A. (FR) | 2001-11-29 | — | — | US | disclosed |
| EP-1154771-A1 | NITROSATED AND NITROSYLATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2001085013-A2 | INFRARED THERMOGRAPHY AND METHODS OF USE | NITROMED, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
| US-20010041726-A1 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | NICOX S.A. (FR) | 2001-11-15 | — | — | US | disclosed |
| EP-1140066-A1 | NITROSATED AND NITROSYLATED H2 RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6297260-B1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED, INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1126838-A1 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2001045703-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1109542-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1109543-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001017528-A1 | METHODS OF TREATING AND PREVENTING CONGESTIVE HEART FAILURE WITH HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE | NITROMED, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000067754-A1 | NITROSATED AND NITROSYLATED POTASSIUM CHANNEL ACTIVATORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000057891-A1 | COMPOSITIONS AND METHODS FOR PRODUCING PLATELETS AND/OR PROPLATELETS FROM MEGAKARYOCYTES | TRUSTEES OF BOSTON UNIVERSITY (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000054773-A1 | DOPAMINE AGONISTS IN COMBINATION WITH NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000051978-A1 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METODS OF USE | NITROMED, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000049993-A2 | NITROSATED AND NITROSYLATED STEROIDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | NITROMED, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000050037-A1 | NITROSATED AND NITROSYLATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000012076-A9 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000028988-A1 | NITROSATED AND NITROSYLATED H2 RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-05-25 | — | — | WO | disclosed |
| WO-2000025776-A1 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000012075-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012076-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
| US-6022969-A | Compositions and methods for treating mast-cell mediated conditions | AXYS PHARMACEUTICALS, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| JP-H08231550-A | 2,6-DIOXABICYCLO(3.3.0)OCTANE DERIVATIVE, ITS PRODUCTION AND HERBICIDE CONTAINING THE SAME AS ACTIVE INGREDIENT | MITSUI TOATSU CHEM INC | 1996-09-10 | — | — | JP | disclosed |
| US-4883796-A | Oxime ethers of 2,6-dioxabicyclo(3.3.0)octanones, and compositions and methods for treatment of a cardiac disease or circulatory with them | HEINRICH MACK NACHF. (DE) | 1989-11-28 | — | — | US | disclosed |
| EP-0230557-A3 | 2,6-Dioxabicyclo[3.3.0]octane derivatives, their preparation and use as medicament | Heinrich Mack Nachf. (DE) | 1988-08-24 | — | — | EP | disclosed |
| EP-0230557-A2 | 2,6-Dioxabicyclo[3.3.0]octane derivatives, their preparation and use as medicament | Heinrich Mack Nachf. (DE) | 1987-08-05 | — | — | EP | disclosed |
| EP-0230557-A2 | 2,6-Dioxabicyclo[3.3.0]octane derivatives, their preparation and use as medicament | Heinrich Mack Nachf. (DE) | 1987-08-05 | — | — | EP | disclosed |
| EP-0230557-A2 | 2,6-Dioxabicyclo[3.3.0]octane derivatives, their preparation and use as medicament | Heinrich Mack Nachf. (DE) | 1987-08-05 | — | — | EP | disclosed |
| EP-0230557-A2 | 2,6-Dioxabicyclo[3.3.0]octane derivatives, their preparation and use as medicament | Heinrich Mack Nachf. (DE) | 1987-08-05 | — | — | EP | disclosed |